KR101855821B1 - Composition for relieving of menopausal symptoms and improving blood circulation - Google Patents
Composition for relieving of menopausal symptoms and improving blood circulationInfo
- Publication number
- KR101855821B1 KR101855821B1 KR1020170026509A KR20170026509A KR101855821B1 KR 101855821 B1 KR101855821 B1 KR 101855821B1 KR 1020170026509 A KR1020170026509 A KR 1020170026509A KR 20170026509 A KR20170026509 A KR 20170026509A KR 101855821 B1 KR101855821 B1 KR 101855821B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- ginseng
- blood
- blood circulation
- ganoderma lucidum
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 230000017531 blood circulation Effects 0.000 title claims abstract description 26
- 206010027304 Menopausal symptoms Diseases 0.000 title claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 33
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 29
- 235000013402 health food Nutrition 0.000 claims abstract description 14
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 12
- 244000291564 Allium cepa Species 0.000 claims abstract 2
- 235000008434 ginseng Nutrition 0.000 claims description 32
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 27
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 26
- 240000008397 Ganoderma lucidum Species 0.000 claims description 19
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 19
- 208000024891 symptom Diseases 0.000 claims description 12
- 229920002472 Starch Polymers 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 239000004382 Amylase Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241000208340 Araliaceae Species 0.000 claims 1
- 240000006439 Aspergillus oryzae Species 0.000 claims 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 235000018865 Angelica gigas Nutrition 0.000 abstract description 11
- 240000001810 Angelica gigas Species 0.000 abstract description 10
- 235000013399 edible fruits Nutrition 0.000 abstract description 8
- 244000237330 gutta percha tree Species 0.000 abstract description 2
- 240000005748 Achyranthes aspera Species 0.000 abstract 1
- 235000005517 Achyranthes aspera Nutrition 0.000 abstract 1
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 244000241872 Lycium chinense Species 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000405911 Rehmannia glutinosa Species 0.000 abstract 1
- 240000004371 Panax ginseng Species 0.000 description 32
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 30
- 230000000694 effects Effects 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 206010020772 Hypertension Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 241000234282 Allium Species 0.000 description 10
- 229930182490 saponin Natural products 0.000 description 10
- 235000017709 saponins Nutrition 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 9
- 150000007949 saponins Chemical class 0.000 description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 description 8
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 8
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 241000382455 Angelica sinensis Species 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 240000002045 Guettarda speciosa Species 0.000 description 6
- 244000061456 Solanum tuberosum Species 0.000 description 6
- 235000002595 Solanum tuberosum Nutrition 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 235000020710 ginseng extract Nutrition 0.000 description 6
- 241000411851 herbal medicine Species 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 240000001982 Aspergillus oryzae var. oryzae Species 0.000 description 5
- 244000298479 Cichorium intybus Species 0.000 description 5
- 235000007542 Cichorium intybus Nutrition 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009245 menopause Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000009429 Ginkgo biloba extract Substances 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940068052 ginkgo biloba extract Drugs 0.000 description 4
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 4
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 240000000031 Achyranthes bidentata Species 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 235000007516 Chrysanthemum Nutrition 0.000 description 3
- 102400000739 Corticotropin Human genes 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 244000170916 Paeonia officinalis Species 0.000 description 3
- 235000006484 Paeonia officinalis Nutrition 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000002270 ergogenic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical group 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- -1 panaxadiol saponins Chemical class 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 241000544270 Angelica acutiloba Species 0.000 description 2
- 244000061520 Angelica archangelica Species 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000008392 Aspergillus oryzae var oryzae Nutrition 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- 241001573881 Corolla Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 244000236655 Diospyros kaki Species 0.000 description 2
- ZERULLAPCVRMCO-UHFFFAOYSA-N Dipropyl sulfide Chemical compound CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 241001504592 Trachurus trachurus Species 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001627 cerebral artery Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005868 electrolysis reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940107131 ginseng root Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000012015 potatoes Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- VNFYMAPAENTMMO-UHFFFAOYSA-N 5-chloro-2-methylquinoline Chemical compound ClC1=CC=CC2=NC(C)=CC=C21 VNFYMAPAENTMMO-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000121157 Achyranthes japonica Species 0.000 description 1
- 241001499808 Allium atrorubens Species 0.000 description 1
- 241000981138 Allium flavum Species 0.000 description 1
- 244000151012 Allium neapolitanum Species 0.000 description 1
- 241001500843 Allium parvum Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 240000001548 Camellia japonica Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 240000005125 Myrtus communis Species 0.000 description 1
- 235000013418 Myrtus communis Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- SYFJYASKXNAXKC-UHFFFAOYSA-N Panaxadiol Natural products CC1(C)CCCC(O1)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CCC34C SYFJYASKXNAXKC-UHFFFAOYSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- 241000201976 Polycarpon Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241001480055 Quercus mongolica Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940008075 allyl sulfide Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000001555 commiphora myrrha gum extract Substances 0.000 description 1
- 235000018597 common camellia Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000005058 diapause Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000015598 salt intake Nutrition 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 239000013306 transparent fiber Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 여성 갱년기 증상 개선 및 혈액순환 증진을 위한 건강식품 조성물에 관한 것으로서, 더욱 상세하게는 홍삼, 당귀, 작약 추출물을 베이스로 하여 상승 효과를 낼 수 있는 개량된 여성 갱년기 증상 개선 및 혈액순환 증진을 위한 건강식품 조성물에 관한 것이다.The present invention relates to a health food composition for improving female menopausal symptoms and improving blood circulation. More particularly, the present invention relates to an improved composition for improving female climacteric symptoms and blood circulation which can produce a synergistic effect based on red ginseng, ≪ / RTI >
갱년기(climacteric)란 내분비 증후군의 일종으로 난소기능의 전반적이고 점진적인 감소가 일어나 생리적 기능 및 성기능이 감소 내지 소실되는 과도기를 말하며, 갱년기의 한 과정으로 난소기능의 정지 후에 일어나는 생리의 영구적인 정지인 폐경(menopause)이 오게 된다. 폐경기에는 에스트로겐 생성의 감소, 난포자극호르몬(follicular stimulating hormone, FSH) 및 황체화호르몬(luteininzing hormone, LH)의 상승 등 호르몬의 변화에 따라 급만성 증상이 나타날 수 있다. 즉, 초기증상으로 열성홍조(hot flush), 야간 발한(night sweat) 등의 혈관 운동성 증상(vasomotor symptom)과 불안감, 집중력 감퇴, 우울증 등의 심리적 증상(psychological symptom)이 나타날 수 있으며, 폐경 수년 내에 나타나는 비뇨생식계 및 표피증상이, 폐경 수년 후에는 골다공증, 심장혈관 및 뇌혈관 질환 등이 있을 수 있다.The term "climacteric" refers to a type of endocrine syndrome that is characterized by a general and gradual decrease in ovarian function, resulting in a decrease in physiological function and sexual function. The term "climacteric" refers to a period of menopause which is a permanent stoppage of menstruation (menopause) will come. Postmenopausal women may have acute chronic symptoms due to changes in hormones, such as decreased estrogen production, follicular stimulating hormone (FSH), and elevated luteininzing hormone (LH). That is, the initial symptoms may include vasomotor symptoms such as hot flush and night sweat, psychological symptoms such as anxiety, loss of concentration, and depression, and within a few years after menopause There may be cases of osteoporosis, cardiovascular and cerebrovascular disease after menopausal years and menopausal and epidermal manifestations.
여성의 갱년기 증상을 개선하기 위한 치료요법으로 호르몬 대체요법, 비스테로이드계 제제에 의한 치료법 등이 개발되어 있으며, 그 중에 에스트로겐을 투여하는 호르몬 대체요법이 가장 효과적인 방법으로 알려져 있다. 그러나, 상기 치료요법에 따라 장기간 약물을 사용하면 자궁내막암, 유방암, 고혈압, 혈전증, 담뇨계 결석 등을 일으킬 수 있으며, 또한 월경성 출혈이 나타날 수 있고, 난소 과잉자극 등의 부작용으로 인하여 의사의 처방 없이는 복용할 수 없다는 문제점이 있다.Hormone replacement therapy and non-steroid therapy have been developed to improve women's menopausal symptoms. Among them, estrogen replacement therapy is known to be the most effective method. However, the use of long-term medicines according to the above-mentioned therapeutic regimen can cause endometrial cancer, breast cancer, hypertension, thrombosis, gallbladder stone, etc., and also may cause mild bleeding and ovarian hyperstimulation, There is a problem that it can not be taken without prescription.
이러한 약물의 치료요법에 의한 문제점을 극복하기 위하여 천연 생약을 주성분으로 하는 여성 갱년기 증상의 개선제의 개발이 시도되고 있으며, 그 중 홍삼은 여러 가지 갱년기 증상의 개선에 유용한 것으로 알려져 있다.(The Society for Korean Ginseng. 1990 ; 20p - 24p)In order to overcome the problems caused by the therapeutic treatment of these drugs, development of an agent for improving the symptoms of female menopausal symptoms based on natural herbal medicine has been attempted, and it is known that red ginseng is useful for the improvement of various menopausal symptoms (The Society for Korean Ginseng 1990; 20p - 24p)
또한, 예로부터 전래되어 오고 있는 한방 의학서인 방약합편 등에 수재되어 있는 당귀작약산은 여성의 갱년기 증상에 효과가 있는 것으로 알려져 있고, 이에 여성 갱년기 증상의 개선에 관하여 당귀작약산과 홍삼을 병용 투여한 임상예가 보고된 바 있다.(The Ginseng Review. 1991 ; vol 18 : 95p - 97p)In addition, it is known that the herbal medicine, which has been introduced from ancient times, is effective for the menopausal symptom of women, and the clinical example of the combination treatment of Dangguo peach acid and red ginseng (The Ginseng Review, 1991; vol 18: 95p-97p).
또한, 대한민국 특허공개공보 제2003-0023297호에는 이소플라빈을 함유한 대두추출물 및 홍삼추출물을 함유하는 갱년기 증후군 개선용 조성물이 제시되어 있으며, 특히, 본 발명자의 일부는 홍삼, 이소플라본, 당귀작약산을 주성분으로 함유하여 제조된 홍삼복방제품이 폐경기 증후군 환자에게 가장 효과가 있음을 제시한 바 있다.(대한폐경학회잡지, 8권 1호, 2002. 3. p46-p58)Korean Patent Laid-Open Publication No. 2003-0023297 discloses a composition for improving menopausal syndrome containing soybean extract and red ginseng extract containing isoflavin. Particularly, the inventors of the present invention have found that red ginseng, isoflavone, The Korean Society of Postmenopausal Sciences, Journal of the Korean Society of Menopause, Vol. 8, No. 1, 2002. 3. p46-p58)
한편, 상기 생약재를 주성분으로 하는 종래기술은 약물에 의한 치료요법보다 부작용을 감소시킬 수는 있으나, 여성의 갱년기 증상을 개선시키기 위한 의약적 효과는 미미하기 때문에 의사의 처방이 없이도 갱년기 여성들에게 호르몬의 불균형을 미연에 방지하면서 약물의 중독이나 부작용의 우려 없이 효과적으로 여성 갱년기 증상을 개선시킬 수 있도록 기능성 식품의 개발이 시도되고 있다.On the other hand, the prior art based on the above-mentioned herbal medicines can reduce side effects rather than therapeutic treatment with drugs, but the medicinal effect for improving the symptoms of women's menopause is insignificant. Therefore, Development of a functional food has been attempted so as to effectively prevent women's menopausal symptoms without fear of drug poisoning or side effects while preventing imbalance.
또한 혈액순환 (the circulation of blood)이란 혈액이 심장을 중심으로 혈관을 따라 우리의 신체를 순환하는 것으로 산소를 신체 각 조직에 공급하고 탄산가스를 방출하고, 영양소를 보급하고 대사 산물을 방출하며, 여러 내분비선에서 호르몬을 운반하여 특정기관의 기능을 조절하며 그밖에 병원균 조절작용과 체온조절, 삼투압조절, 수분조절 등의 기능을 수행하는 과정이다.In addition, the circulation of blood (blood circulation around the heart around the blood vessels in our body to supply oxygen to the body tissues, carbon dioxide emissions, nutrients, and release metabolism, It transports hormones from various endocrine glands to regulate the functions of specific organs, as well as to regulate pathogens, regulate body temperature, control osmotic pressure, and regulate moisture.
혈관은 동백, 모세혈관, 정맥으로 구성되어 있다. 동맥은 외탄력선판과 결합조직으로 되어 있는 외막, 평활근이 많고 그안에 다수의 탄력섬유를 함유하고 있는 중막, 제일 안쪽의 내피세포와 그것을 둘러싸고 있는 결합조직과 탄력섬유가 모여서 내강성판으로 되어 있는 내막으로 이루어져 있다. 모세혈관은 소동맥과 소정맥이 연결된 것으로 그물모양으로 가늘게 가지가 나 있으며 직경 0.008∼0.02mm의 가는 관으로서 적혈구가 1∼2줄로 통과될 정도이고 육안으로는 보이지 않으며, 이 모세혈관을 통해서 혈액 중의 산소와 영양분은 조직내로 보내지고 조직에서 만들어진 CO2 나 노폐물은 혈관으로 들어온다. 정맥의 외막은 비교적 두껍고 내막과 중막은 얇으며 압력이 없고 다른 혈관에 비해 혈류가 약하여 심장보다 낮은 부분의 정맥에서 역류할 위험성이 있기 때문에 역류 방지용 판막(valve)이 붙어 있다.The blood vessels consist of camellias, capillaries, and veins. The artery is composed of an outer membrane composed of an external elastic plate and connective tissue, a middle membrane containing many smooth muscles and a large number of elastic fibers therein, an inner membrane of the innermost endothelial cells, a connective tissue surrounding the inner membrane, Lt; / RTI > The capillary blood vessels are connected by a small artery and a small artery. They have a narrow net shape and are thin tubes with a diameter of 0.008-0.02mm. They are passed through 1 or 2 lines of red blood cells and are not visible to the naked eye. And nutrients are sent into the tissues and the CO 2 or waste produced by the tissues enters the blood vessels. The outer membrane of the vein is relatively thick, the inner membrane and the middle membrane are thin, and there is a valve to prevent backflow because there is no pressure and there is a risk of backflow in the vein lower than the heart due to weaker blood flow than other blood vessels.
혈액순환장애란 상기 혈관들이 탄력을 잃고 내벽에 콜레스테롤 등이 침착되어 혈관 내강이 좁아져 혈액순환이 원활치 못한 것을 말한다. 가장 대표적인 순환기계 질환으로 꼽히는 뇌졸증[중풍(中風), 풍(風)]은 뇌혈관이 터지거나 혈전이나 지방으로 막히는 것이다. 뇌졸증은 암, 심장 질환과 함께 한국인의 3대 사망원인 중의 하나이다. 뇌졸증은 뇌동맥벽이 압력 때문에 파열 하여 뇌조직 내부에 혈종이 형성되어 주위의 뇌조직을 압박함으로써 생기는 출혈성 뇌졸증과, 뇌동맥의 일부가 좁아지거나 막혀서 그 동맥을 통하여 산소와 영양을 공급받아 뇌조직이 괴사를 일으키는 허혈성 뇌졸증의 두가지가 있다. 출혈성 뇌졸증은 뇌출혈과 지주막하출혈의 두가지로 더 분류되며 허혈성 뇌졸증은 뇌경색과 일과성 뇌허혈발작으로 더 분류된다.Blood circulation disorder means that blood vessels lose their elasticity and cholesterol is deposited on the inner wall to narrow blood vessel lumen, resulting in poor blood circulation. Stroke [paralysis, wind], which is considered to be one of the most typical circulatory diseases, is a cerebrovascular disorder or clogging of blood clots or fat. Stroke, along with cancer and heart disease, is one of the three causes of death in Koreans. Stroke is caused by hemorrhagic stroke caused by pressure rupture of the wall of the cerebral artery due to pressure and formation of hematoma inside the brain tissue and peripheral cerebral tissue, and a part of the cerebral artery becomes narrowed or blocked, oxygen and nutrients are supplied through the artery, There are two types of ischemic stroke. Hemorrhagic stroke is classified into two categories: cerebral hemorrhage and subarachnoid hemorrhage. Ischemic stroke is further divided into cerebral infarction and transient ischemic attack.
뇌출혈을 초래하는 보다 일반적인 증상이 고혈압과 동맥경화이다. 고혈압은 수축기 혈압이 140이상이거나 이완기 혈압이 90이상으로 지속되는 질환을 말하며 이완기 혈압이 90∼104인 경우 경중 고혈압, 105∼110인 경우 중증도 고혈압, 110이상일 때를 중증 고혈압이라고 분류한다. 전체 고혈압 환자의 90%가 원인을 알 수 없는 본태성(원발성, 일차성) 고혈압이고, 원인을 뚜렷이 알 수 있는 경우가 속발성(이차성) 고혈압이다. 혈압은 나이가 들수록 증가하며 유전적 성향이 많고, 조급한 성격, 비만, 고염분섭취, 정신적 스트레스, 흡연, 음주, 신장의 질환, 갈색 세포종, 경구 피임약의 사용, 원발성 고알도스테롤혈증 등 원인이 되어 고혈압이 발생한다.The more common symptoms that lead to hemorrhage are hypertension and atherosclerosis. Hypertension refers to a disorder in which the systolic blood pressure is greater than 140 or the diastolic blood pressure is greater than 90. It is classified as severe hypertension when the diastolic blood pressure is 90 to 104, severe hypertension when the blood pressure is 105 to 110, and severe hypertension when the blood pressure is 110 or more. Ninety percent of patients with total hypertension are baseline (primary, primary) hypertension whose cause is unknown, and the most obvious cause is secondary (secondary) hypertension. Blood pressure increases with age and has a high genetic tendency. It is caused by abrupt personality, obesity, high salt intake, mental stress, smoking, drinking, kidney disease, pheochromocytoma, oral contraceptive use, primary hyperaldosteronism Hypertension occurs.
동맥벽이 굳어져서 탄력성이 감소하고 내면에 지방이 끼이고 이상 조직이 증식하여 내경이 좁아지는 현상을 동맥경화라 한다. 다소간의 동맥경화현상은 노화 현상으로서 고령일수록 동맥경화성 질환의 빈도가 높아지며 동시에 여러 장기가 침범된 현상을 볼 수 있으며 이런 현상이 뇌혈관에서 생기면 뇌졸증이 된다. 이밖에 심장병과 당뇨병도 고혈압, 동맥경화 등과 밀접한 연관을 가진 순환기계 질환이다.Arteriosclerosis is a phenomenon in which arterial walls are hardened, elasticity is reduced, fat is trapped on the inner surface, and abnormal tissue grows to narrow the inner diameter. Some of the atherosclerosis phenomenon is aging phenomenon. As the aging progresses, the incidence of arteriosclerosis increases, and at the same time, many organs are invaded. If this phenomenon occurs in the cerebral blood vessels, it becomes a stroke. In addition, heart disease and diabetes are closely related to hypertension and atherosclerosis.
강직현상 발생 메카니즘에 대해서는 아직 명확하지 않으나, 신경의 과도한 자극, 근육피로 및 자율적인 근긴장 이상에 의해 말초혈관의 과도한 수축, 근육내에서의 혈액순환 장해, 충혈을 유발하게 되어 특이한 강직현상이 일어난다. 따라서, 근육 강직 현상을 없애기 위해서 혈액순환을 개선하는 것이 효과적이다. 마사지, 온욕(溫浴)요법, 습포제 사용, 전기자극 및 약물 투여 등의 치료방법으로서는 소요의 효과를 얻기가 어렵고, 혹은 이들 중 몇가지 환자가 전문적인 치료를 위해 병원에 가야하므로 번잡스럽다.The mechanism of the stiffness is not clear yet, but excessive stiffness of the nerve, muscle fatigue and autonomic dystonia cause excessive shrinkage of the peripheral blood vessels, blood circulation in the muscles, and congestion. Therefore, it is effective to improve blood circulation in order to eliminate the muscle rigidity phenomenon. It is difficult to obtain a desired effect as a therapeutic method such as massage, warm bath treatment, use of a poultice, electric stimulation and drug administration, or it is troublesome that some of them have to go to a hospital for professional treatment.
따라서 본 발명이 해결하고자 하는 과제는 여성 갱년기 증상 개선 및 혈액순환 증진을 위한 건강식품 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a health food composition for improving female menopausal symptoms and promoting blood circulation.
상기 기술적 과제를 달성하기 위하여 본 발명은,According to an aspect of the present invention,
물 20ℓ에 양파 4kg, 홍삼 1,200g, 두충 200g, 우슬 200g, 당귀 100g, 숙지황 100g, 작약 200g, 천궁 200g, 구기자 200g, 산수유 150g을 넣은 혼합물을 90℃에서 48시간 추출하여 제조되는 것을 특징으로 하는 여성 갱년기 증상 개선 및 혈액순환 증진을 위한 건강식품 조성물을 제공한다.A mixture prepared by adding 4 kg of onion, 1,200 g of red ginseng, 200 g of persimmon, 200 g of horse mackerel, 100 g of Angelica gigas, 100 g of Ganoderma lucidum, 100 g of Ganoderma lucidum, 100 g of Ganoderma lucidum, 200 g of Ganoderma lucidum, 200 g of Gugija and 150 g of Sansui oil to 20 ℓ of water is extracted at 90 캜 for 48 hours A health food composition for improving female menopausal symptoms and promoting blood circulation.
본 발명에 따른 여성 갱년기 증상 개선 및 혈액순환 증진을 위한 건강식품 조성물에 있어서, 상기 혼합물에 돼지감자 착즙액과 치커리 착즙액을 1:1 중량비로 혼합한 후에 a-amylase를 첨가하여 전분을 분해한 다음 Aspergillus oryzae var. oryzae 곰팡이 균을 상기 착즙액에 10중량% 접종하여 50℃에서 48시간 동안 발효한 다음에 여과한 발효액 5ℓ부가한 후 다음에 50℃에서 48시간 동안 발효한 후 상기 추출이 이루어지는 것이 바람직하다.In a health food composition for improvement of female climacteric symptoms and improvement of blood circulation according to the present invention, a sweet potato juice and a chicory juice are mixed at a weight ratio of 1: 1, and a starch is decomposed by adding a-amylase Next Aspergillus oryzae var. oryzae fungus is inoculated in the juice by 10% by weight, fermented at 50 ° C for 48 hours, added with 5ℓ of the filtered fermentation broth, and then fermented at 50 ° C for 48 hours, followed by extraction.
본 발명에 따른 여성 갱년기 증상 개선 및 혈액순환 증진을 위한 건강식품 조성물에 있어서, 상기 물은 수소수인 것이 바람직하다.In the health food composition for improvement of female menopausal symptoms and improvement of blood circulation according to the present invention, the water is preferably hydrogenated water.
본 발명에 따른 조성물은 여성 갱년기 증상 개선 및 혈액순환 증진에 매우 유용하고 효과적이어서 중장년층의 여성을 위한 우수한 건강식품 조성물이다.The composition according to the present invention is an excellent health food composition for middle-aged women because it is very useful and effective for improving female menopausal symptoms and improving blood circulation.
이하 본 발명을 실시하기 위한 구체적인 내용을 설명하기로 한다.Hereinafter, the present invention will be described in detail.
기본적으로 본 발명은Basically,
물 20ℓ에 양파 4kg, 홍삼 1,200g, 두충 200g, 우슬 200g, 당귀 100g, 숙지황 100g, 작약 200g, 천궁 200g, 구기자 200g, 산수유 150g을 넣은 혼합물을 90℃에서 48시간 추출하여 제조되는 것을 특징으로 하는 여성 갱년기 증상 개선 및 혈액순환 증진을 위한 건강식품 조성물을 제공한다.A mixture prepared by adding 4 kg of onion, 1,200 g of red ginseng, 200 g of persimmon, 200 g of horse mackerel, 100 g of Angelica gigas, 100 g of Ganoderma lucidum, 100 g of Ganoderma lucidum, 100 g of Ganoderma lucidum, 200 g of Ganoderma lucidum, 200 g of Gugija and 150 g of Sansui oil to 20 ℓ of water is extracted at 90 캜 for 48 hours A health food composition for improving female menopausal symptoms and promoting blood circulation.
본 발명에서 사용되는 상기 양파는 서아시아 또는 지중해 연안이 원산지라고 추측하고 있으나 아직 야생종이 발견되지 않아 확실하지 않다. 재배 역사는 매우 오래되어 기원전 3000년경의 고대 이집트 분묘의 벽화에는 피라미드를 쌓는 노동자에게 마늘과 양파를 먹였다는 기록이 있고, 그리스에서는 기원전 7∼8세기부터 재배하였다고 한다. 비늘줄기는 품종에 따라 다소 차이가 있으나 납작한 둥근 모양 또는 둥근 모양이며 겉에 얇은 막질(膜質:얇은 종이처럼 반투명한 것)의 자줏빛이 도는 갈색 껍질이 있고 안쪽의 비늘은 두꺼우며 층층이 겹쳐지고 매운 맛이 난다. 잎은 속이 빈 원기둥 모양이고 짙은 녹색이며 꽃이 필 때 마르고 밑 부분이 두꺼운 비늘 조각으로 되어 있다. 꽃은 9월에 흰색으로 피고 잎 사이에서 나온 꽃줄기 끝에 산형꽃차례를 이루며 많은 수가 달려 공처럼 둥근 모양이다. 꽃줄기는 원기둥 모양이고 높이가 50∼100cm에 달하며 아랫부분이 부풀어 있으며 그 밑에 2∼3개의 잎이 달린다. 화피는 6개로 갈라지고, 갈라진 조각은 달걀을 거꾸로 세운 모양의 바소꼴이며 수평으로 퍼진다. 수술은 6개이고 그 중 3개의 수술대 밑 양쪽에 잔 돌기가 있으며, 암술은 1개이다. 품종은 비늘줄기가 둥근 모양과 납작하게 둥근 모양, 비늘줄기의 껍질이 붉은빛인 것과 노란 것, 그리고 흰 것 등으로 나뉜다. 또한 맛에 따라 단 양파와 매운 양파로 나뉜다. 일반적으로 식용하는 양파 품종은 노란양파, 붉은 양파, 흰 양파, 작은 양파의 4가지 품종이 주류를 이룬다. 수확은 주로 6∼7월에 잎이 쓰러지고 약간 녹색을 지닐 때 하는데, 비늘줄기가 크기 전에 뽑아서 잎을 식용하는 것도 있다. 양파는 주로 비늘줄기를 식용으로 하는데, 비늘줄기에서 나는 독특한 냄새는 이황화프로필·황화알릴 등의 화합물 때문이다. 이것은 생리적으로 소화액 분비를 촉진하고 흥분·발한·이뇨 등의 효과가 있다. 또한 비늘줄기에는 각종 비타민과 함께 칼슘·인산 등의 무기질이 들어 있어 혈액 중의 유해 물질을 제거하는 작용이 있다. 비늘줄기는 샐러드나 수프, 그리고 고기 요리에 많이 사용되며 각종 요리에 향신료 등으로 이용된다. 잎은 100g 중에 비타민A 5,000IU, 비타민C 45mg, 칼슘 80mg, 마그네슘 24mg, 칼륨 220mg이 들어 있다. 본 발명에서 양파는 껍질을 포함한 비늘줄기를 의미한다.The onion used in the present invention is presumed to be originated in West Asia or the Mediterranean coast, but it is not certain because wild type was not found yet. The cultivation history is so long that there are records that ancient Egyptian burial mounds around 3000 BC fed garlic and onion to pyramid workers, and grew in Greece from the 7th to 8th centuries BC. Scale stem is somewhat different according to varieties, but it has a flat round or round shape. It has thin purple color (semitransparent like translucent film) on its surface. Its inner scales are thick, This is fascinating. Leaves are hollow cylinders, dark green, dry when flowers are bloomed, and sculpted at the bottom. The flower blooms in September, and the flower stalk which comes out from the leaf forms a mountain inflorescence, and many numbers are round like a ball. The flower stalks are cylindrical and have a height of 50 ~ 100cm and the lower part is swollen with 2 ~ 3 leaves under it. The horns are divided into 6 pieces, and the split pieces are basically shaped like inverted eggs and spread horizontally. There are six stamens, of which there are three on each side under the operating table, and one pistil. The varieties are divided into a round shape of the stem of the scales, a flat round shape, a red color of the scales stem, a yellow one, and a white one. It is also divided into sweet onion and spicy onion depending on taste. Generally, edible onion varieties are four varieties of yellow onion, red onion, white onion and small onion. The harvest is mainly from June to July when the leaves fall down and have a little green color. Some of the leaves of the scales are picked before the leaves are edited. Onion is mainly used for edible scales. The unique odor from scales is due to compounds such as disulfide propyl sulfide and allyl sulfide. It physiologically promotes the secretion of digestive juices and has effects such as excitement, sweating, and diuretic. In addition, the scales stem contains various vitamins and minerals such as calcium and phosphoric acid, and it has action to remove harmful substances in blood. Scale stalk is used in salads, soups, and meat dishes, and is used as a spice for various dishes. The leaf contains 5,000 IU of vitamin A, 45 mg of vitamin C, 80 mg of calcium, 24 mg of magnesium, and 220 mg of potassium in 100 g of leaves. In the present invention, the onion means a stem of a scales including a shell.
본 발명에서 사용되는 홍삼은 인삼을 쪄서 말린 붉은 인삼을 말하는 것으로서, 인삼은 두릅나무과 인삼속 식물의 뿌리를 말한다. 재배산지에 따라 고려인삼(한반도), 미국삼(미국 및 캐나다), 전칠삼(중국), 죽절삼(일본) 등의 명칭으로 불리우며, 인삼의 원형을 유지하는 1차 가공방법에 따라 수삼, 홍삼, 백삼, 당삼 및 봉밀삼 등으로 구분된다. 인삼에 대한 연구는 미국의 Garriques에 의하여 시작되었다. Garriques는 1854년 인삼으로부터 비결정성 사포닌 혼합물을 분리하여 panaquilon이라고 명명하였고 1960년대 일본의 시바다와 다나까(1963, 1966)는 고려인삼으로부터 12종의 개별사포닌 성분(ginsenoside)을 분리하고 화학적 구조를 밝혀내는데 성공하여 인삼의 단일 성분별 약리 효능 연구를 가능하게 하였다. 고려인삼(Panax ginseng C.A. Meyer)은 과거부터 우리나라를 비롯하여 중국, 일본 등에서주로 건강증진을 위한 목적으로 널리 사용하여 왔다. 인삼의 유효성분들은 인삼의 종류, 뿌리 부위, 수확 년생, 수확 시기, 제조방법에 따라 현저한 차이가 있는 것으로 알려져 있는데, 인삼의 연근별로는 일반적으로 저년근에는 당 함량이 많고 고년근에서는 사포닌 함량이 많은 것으로 알려져 있다. 또한, 수삼을 증기로 쪄서 건조시킨 홍삼과 백삼 간에는 조사포닌 함량이나 진세노사이드의 종류에서 차이를 보이는 것으로 알려져 있다. 일반적으로, 미삼류에는 조사포닌이 10~15% 또는 그 이상이며 동체에는 3~5%로 보고되고 있다. 다시 말하면, 조사포닌이 세근에는 약 13%, 지근에는 6.5%, 동체에 4% 정도 함유되어 있으며 비사포닌 활성성분은 세근에 비해 동체에 많이 함유되어 있다고 한다. 건강기능식품에서 말하는 ‘홍삼’은 인삼(Panax ginseng C.A. Meyer)을 원재료로 사용하여, 말리지 않은 수삼을 증기 또는 기타 방법으로 쪄서 익혀 말린 것이다. 이를 분말화하거나 물이나 주정으로 추출하여 농축 또는 발효하여 식용에 적합하도록 만들어야 하며, 진세노사이드 Rg1과 Rb1의 합이 0.8~34㎎/g이 되도록 관리하여야 한다. 진세노사이드의 규격은 실제 실험 결과(분말 Rg1:2.0~4.0㎎/g, Rb1:4.0~12.0㎎/g / 물 추출물 Rg1:0.3~6.0㎎/g, Rb1:0.5~10.0㎎/g / 주정 추출물 Rg1:0.3~13.0㎎/g, Rb1:0.5~21.0d㎎/g)를 바탕으로 설정하였다. 원재료로 사용하는 인삼근은 ‘인삼산업법’에 적합하여야 하며 4년근 이상의 것으로 춘미삼, 묘삼, 삼피, 인삼박은 사용할 수 없으며 병삼인 경우에는 병든 부분을 제거하고 사용할 수 있다. 홍삼은 “피로회복”, “면역력 증진”, “혈소판 응집 억제를 통한 혈액 흐름에 도움”의 기능성이 인정되었다. 서양에서는 인삼의 기능성에 대하여 ergogenic이라는 말로 표현하기도 한다. Ergogenic은 그리스어로 일(Ergo)과 생산(Gen)의 합성어로, 보통 일할 수 있는 잠재력을 향상시킨다는 의미이며, Bahrke 등(2000)은 인삼연구문헌에 대한 분석연구에서 인삼의 ergogenic effect를 운동 능력, 스트레스반응효과, 인지능력, 심리안정 등의 영역으로 설정하기도 하였다. 이에 인삼의 기능성자료를 검토한 결과 현재까지 수행된 인체적용시험 중심으로 인삼 및 홍삼은 육체적 피로에 대한 회복 효과만이 기능성을 인정할 수 있으며 스트레스 및 심리안정에 관한 기능성은 아직까지 인체에서 충분히 연구되지 않은 것으로 판단되었다. Popov 등(1973), Hu 등(1976), Li 등(1973), Perry 등(1980), Baranov 등(1982)은 인삼이 실험동물과 사람에서 corticotropin(부신피질자극호르몬; ACTH)과 cortisol 등 스트레스와 같은 외부자극에 대해 신체가 저항할 수 있도록 하는 호르몬의 분비를 증가시킨다고 보고하였다. 실제로 Liang 등(2005)은 20~35세 가량의 건강한 사람 29명에게 하루 인삼 추출물 1350㎎을 1개월 동안 섭취시켜 운동 중 평균 혈압이 감소하고 최대산소섭취량, 운동 유지 시간이 증가함을 관찰하였으며, Marasco 등(1996)은 건강한 사람 501명에게 12주 동안 200㎎의 인삼 추출물을 섭취시켜 피로회복과 관련된 삶의 질이 증가되는 것을 확인하였다. Cherdrungsi 등(1995)은 45명의 대학생에게 8주 동안 300㎎의 인삼 추출물을 섭취시킨 경우 대조군에 비하여 최대산소섭취량이 증가하고 다리 근력이 증가하였다고 보고하였다. 김형돈 등(2004)은 홍삼 추출물을 50㎎/㎏씩 3주간 매일 섭취하고 경사가 있는 트레드밀에서 지속적으로 달리기를 실시한 결과 혈중 creatinine kinase 농도 회복이 빨라 근 손상 후 회복에 도움이 될 수 있다고 보고하였다. 또한, 이 이외의 인체적용시험을 대상으로 분석한 결과, 건삼을 하루에 2g 이상, 8주 이상 섭취하면 유의적인 피로회복 기능성이 확인되는 것으로 드러났다(Popov 등, 1973;Revers 등, 1976;Dorling 등, 1980; Sandberg 등, 1980;Forgo 등, 1980;Forgo 등, 1981;Forgo 등, 1982). 그러나, 낮은 용량, 짧은 기간의 투여, 소수의 피험자 등으로 이루어진 시험에서는 개선 효과가 나타나지 않았다. 평균 연령이 23세 정도인 건강인 28명에게 하루에 인삼 추출물 200㎎을 3주 동안 섭취시킨 Allen 등(1998)의 시험에서는 운동 시간, 혈중 젖산 농도 등에서 유의한 개선 효과가 나타나지 않았으며, 이 외에도 Lifton 등(1997), Engels 등(1995), Engels 등(1996), Engels 등(1998)의 연구 결과에서도 이를 확인할 수 있었다. 따라서, 적당한 조건이 충족될 때 인삼추출물이 근력과 유산소 운동 용적을 증진시킨다고 말할 수 있다. 면역조절작용으로서의 인삼은 adaptogen 또는 immunostimulator로서 분류되고 있다. “Adaptogen”이란 우리 몸이 이화학적 또는 생물학적 자극에 대하여 저항성을 갖게 하는 물질을 의미하며 “immunostimulant"는 신체의 감염물질과 같은 이물질에 대항하는 비특이적인 방어작용을 활성화시키는 물질을 뜻한다. Scaglione 등(1990)은 인삼 추출물 200㎎를 8주 동안 섭취시킨 결과 PBMC의 탐식작용이 증가함을 관찰하였고, 1996년의 연구에서 227명을 대상으로 하루에 100㎎을 12주 동안 섭취시켜 NK 세포의 활성이 증가하였다고 보고하였다. Gerald 등(2005)은 미국 인삼으로 제조된 추출물 400㎎을 면역력이 약한 323명에게 4개월 동안 섭취시켜 감기에 걸리는 횟수가 줄어드는 것을 확인하였으며, 감기에 걸린 대상자들도 그 증상 등이 감소되었다고 보고하였다. 서성옥 등(1998)은 소화기계암 수술을 받은 환자들에게 홍삼을 하루에 4500㎎을 6개월간 섭취하게 한 후 면역세포 등을 확인한 결과 T 세포수, NK 세포수, activated T 세포수 등이 유의적으로 증가하였음을 확인하였다. Yu 등(2006)이 동물의 혈소판에 홍삼 추출물을 처리한 결과, 혈소판 응집 유도 물질(콜라겐, 아라키돈산, 트롬빈 등)에 의해 유도된 혈소판 응집 물질을 용량 의존적으로 억제하며, APTT(Activated Partial Thromboplastin Time), PT(Prothrombin Time)에는 영향이 없었다. 혈액응고인자에 작용하는 것이 아니라 혈소판 응집 자체를 억제하는 것을 알 수 있었다. 또한, Park 등(1993)의 연구에서는 홍삼 중 panaxadiol계 사포닌은 정상 성인 혈소판에서 트롬빈에 의한 TXA2 생성을 감소시켰다. 신경섭 등(2007)은 20~65세의 건강인을 대상으로 하루에 홍삼 농축액 3g을 섭취시킨 대조군설정 이중맹검 연구를 수행한 결과, 혈소판 응집이 유의하게 감소되었으며 APTT는 유의차가 없었다고 보고하였다. 또한, 홍삼 제품류를 4~5년 동안 장기 섭취한사람과 섭취하지 않은 사람을 비교한 이정희 등(1998)의 연구에서는 장기섭취군의 혈소판 응집 반응이 유의하게 감소하였으며 혈액응고시간이 유의하게 증가하였다.The red ginseng used in the present invention refers to dried red ginseng by steaming ginseng, and the ginseng refers to the roots of the ginseng and ginseng plants. It is called as Korean Ginseng (Korean peninsula), American Sampler (USA and Canada), Jeollanam (China), Jangseum Sam (Japan) according to the cultivation area. According to the first processing method of maintaining the original shape of ginseng, White ginseng, sugar, and sesame seeds. Research on ginseng began by Garriques of the United States. Garriques separated the amorphous saponin mixture from ginseng in 1854 and named it panaquilon. Shibada and Tanaka (1963, 1966) in Japan in the 1960s separated 12 individual saponin components (ginsenosides) from Korean ginseng and revealed their chemical structure And it was possible to study the pharmacological effects of ginseng by single components. Korean ginseng (Panax ginseng C.A. Meyer) has been widely used for promotion of health in Korea, China, and Japan. The effective components of ginseng are known to be significantly different depending on the type of ginseng, root area, harvest age, harvesting time, and manufacturing method. The ginseng root is generally known to have a high sugar content in low-grade roots and a high saponin content in high roots . In addition, it is known that there is a difference between crude saponin content and ginsenoside type between red ginseng and white ginseng steamed with steam. In general, crude saponin is reported to be 10 to 15% or more crude saponin and 3 to 5% in fuselage. In other words, crude saponin contains about 13% in the fine root, 6.5% in the root, and 4% in the fuselage, and the non-saponin active ingredient is contained in the body much more than the fine root. The 'red ginseng' used in health functional foods is ginseng (Panax ginseng C.A. Meyer) as a raw material and steamed or otherwise steamed the uncooked ginseng to be boiled and dried. It should be powdered, extracted with water or alcohol, concentrated or fermented to make it suitable for edible use, and the sum of ginsenosides Rg1 and Rb1 should be controlled to be 0.8 to 34 mg / g. The standard of ginsenosides was as follows: Powder Rg1: 2.0-4.0 mg / g, Rb1: 4.0-12.0 mg / g / water extract Rg1: 0.3-6.0 mg / g, Rb1: 0.5-10.0 mg / g / Extract Rg1: 0.3 to 13.0 mg / g, Rb1: 0.5 to 21.0 dmg / g). Ginseng roots used as raw materials should conform to the 'Ginseng Industrial Act' and should not be used for more than 4 years old. Chungsam, Seomyeom, Sampy, Ginseng roots can not be used. Red ginseng has been recognized as "functional for restoring fatigue", "improving immunity" and "helping blood flow through inhibition of platelet aggregation". In the West, the function of ginseng is sometimes referred to as ergogenic. Ergogenic is a synonym for Ergo and Genetics in Greek, meaning that it usually improves the potential to work. Bahrke et al. (2000) analyzed the ergogenic effects of ginseng on exercise, Stress response effect, cognitive ability, and psychological stability. As a result of examining the functional data of ginseng, it can be concluded that ginseng and red ginseng can be recognized only by the recovery effect on physical fatigue, and that the function concerning stress and psychological stability is not sufficiently studied in the human body Respectively. In this study, the effects of ginseng on corticotropin (corticotropin, ACTH) and cortisol in experimental animals and humans were investigated by the method of Popov et al. (1973), Hu et al. (1976), Li et al. (1973), Perry et al. (1980) and Baranov et al. And that the body's ability to resist external stimuli such as increased secretion of hormones were reported. In fact, Liang et al. (2005) observed that the average blood pressure decreased and the maximum oxygen uptake and exercise duration increased during the exercise period by taking 1350 mg of ginseng extract per day for 29 healthy people aged 20 to 35 years, Marasco et al. (1996) found that the intake of 200 mg of ginseng extract for 12 weeks increased the quality of life associated with fatigue recovery in 501 healthy subjects. Cherdrungsi et al. (1995) reported that the intake of 300 mg of ginseng extract for eight weeks to 45 college students increased maximum oxygen uptake and increased leg strength compared to the control group. Kim et al. (2004) reported that red ginseng extract ingested 50 mg / kg daily for 3 weeks and continued running in a treadmill with a slope, the recovery of creatinine kinase level in the blood could be quicker to recover after muscle injury. In addition, the results of analyzing the other body application tests revealed that the ingestion of dried ginseng more than 2g / day for more than 8 weeks confirmed significant fatigue recovery function (Popov et al., 1973; Revers et al., 1976; Dorling et al. Forgo et al., 1980; Forgo et al., 1981; Forgo et al., 1982). However, no improvement was observed in tests consisting of low dose, short duration administration, small number of subjects, and the like. In Allen et al. (1998) who consumed 200 mg of ginseng extract for three weeks per day in 28 healthy volunteers with an average age of 23 years, no significant improvement was observed in exercise time and blood lactate concentration. Lifton et al. (1997), Engels et al. (1995), Engels et al. (1996) and Engels et al. Therefore, it can be said that the ginseng extract improves muscle strength and aerobic exercise volume when appropriate conditions are met. Ginseng as an immunoregulatory effect is classified as adaptogen or immunostimulator. "Adaptogen" refers to a substance that makes our body resistant to physiological or biological stimuli, while "immunostimulant" refers to a substance that activates a nonspecific defense against a foreign body such as infectious agents of the body. (1990) observed that the ingestion of 200 mg of ginseng extract for 8 weeks resulted in an increase in the phagocytic activity of PBMC. In a 1996 study, 227 patients received 100 mg / day for 12 weeks, Gerald et al. (2005) found that 400 mg of the extract made from American ginseng was consumed in 323 patients with weak immunity for 4 months, reducing the frequency of colds. (1998) reported that patients who underwent digestive organs surgery received red ginseng at a dose of 4,500 mg per day for six months The number of T cells, NK cells, and number of activated T cells were significantly increased after immunocytochemical examinations. Yu et al. (2006) treated red ginseng extract with platelets in this animal, Dose-dependent inhibition of platelet aggregation induced by substances (collagen, arachidonic acid, thrombin, etc.), and did not affect APTT (Proportional Thromboplastin Time) or PT (Prothrombin Time) In addition, Park et al. (1993) reported that panaxadiol saponins in red ginseng reduced TXA2 production by thrombin in normal adult platelets. . In the control group, the platelet aggregation was significantly decreased and the APTT was not significantly different In the study of Lee, Jung-Hee, et al. (1998) comparing red ginseng products to those who did not take long-term ingestion for 4 to 5 years, platelet aggregation response in the long-term intake group decreased significantly and blood coagulation time Respectively.
본 발명에 사용되는 두충은 두충나무과의 두충나무(Eucommia ulmoides Oliver)의 나무껍질을 말린 약재로서, 이는 옛날에 두중(杜仲)이라는 사람이 이 약을 먹고 득도하였다하여 붙여진 이름이며 사중(思仲), 사선(思仙)이라는 이명도 같은 이야기에서 유래했다. 두충나무는 잎이나 나무껍질에 실 같은 투명한 섬유질이 많아서 목면(木棉)이라고 부르기도 한다. 이 약의 맛은 달고 매우며, 성질은 따듯하다. 간신(肝腎)기능 부족으로 인한 요통, 무릎통, 몸이 차서 생기는 양위(陽萎), 하복냉감, 소변 자주 보는 증, 태동불안, 자궁출혈 등을 치료하며 혈압강하 효과가 있다. 약리작용으로 혈압강하, 항노화, 콜레스테롤강하, 항염, 진정,진통, 면역 조절, 혈액응고, 자궁수축, 항알레르기, 항균작용 등이 보고되었다. 두충은 판상으로 바깥면은 회색 또는 어두운 회색이며 세포주름이 많고 껍질에 작은 구멍인 피공(皮孔)이 있으며 안쪽면은 평활하고 어두운 갈색을 띤다. 꺾으면 끈기 있는 가늘고 흰 섬유질의 실이 생긴다. 두충의 이명으로 두중(杜仲), 사중(思仲), 사선(思仙), 목면(木棉), 석사선(石思仙), 사운피(絲運皮) 등이 있다.The diapause used in the present invention is a drug used to dry the bark of Eucommia ulmoides Oliver, which is a name given to a person who once eats DuPont and eats it, , And the name tsun (仙 仙) comes from the same story. Quercus mongolica is often called cotton because it has a lot of transparent fibers like silk in leaves and bark. The taste of this medicine is very sweet and its quality is warm. There is an effect of lowering blood pressure by treating low back pain due to lack of function of liver (kidney), knee pain, numbness of body, coldness of lower abdomen, urinary frequency, early anxiety, uterine bleeding. Antihypertensive action, anti-aging, cholesterol lowering, anti-inflammation, sedation, pain relief, immune control, blood clotting, uterine contraction, antiallergic and antibacterial activity have been reported. The outer surface is gray or dark gray. There are many cell wrinkles, small pores in the skin, and the inner surface is smooth and dark brown. When broken, a thin, white fiber yarn with tenacity is formed. Duchong 's tinnitus is 仲 中, 四 仲, 四 仙, 綿, masseon, and 運 皮.
본 발명에서 사용되는 우슬은 우리나라에서는 비름과의 쇠무릎(Achyranthes japonica Nakai) 또는 우슬(Achyranthes bidentata Blume:牛膝)의 뿌리를 말하며, 일본에서는 우슬(Acyranthes bidentata Blume:牛膝)과 털쇠무릎(Achyranthes fauriei H. Lev. & Vaniot)을 쓴다. 중국은 우슬(Achyranthes bidentata Blume:牛膝)만을 인정하고 있다. 옛날 뼈나 근육에 대한 병과 간과 신장병에 걸린 환자를 잘 치료하는 의원이 있었는데 자신의 후계자로 삼을 진실한 제자를 찾기위해 시험을 해보기로 했다. 그는 빈털터리 행색으로 제자들의 집에 머무르며 그들의 태도를 지켜보기로 했다. 그 결과 가장 어린 제자만이 돈 없는 스승을 진실하게 대하였다. 이에 감복한 의원은 그에게 한 약초의 효능을 전해주며 "뼈와 근육은 물론이고 간장과 신장의 병을 치료하는 약이니 이 약으로 많은 사람을 구해주거라."라는 말을 남겼다고 한다. 제자는 스승의 뜻대로 이 약초를 잘 써서 명의가 되었으며, 이 약초의 마디의 생김새가 마치 소의 무릎을 닮아 '우슬(牛膝)'이라 불렀다고 한다. 이 약은 냄새가 거의 없고 점액성이다. 맛은 약간 쓰고 시며 성질은 어느 한쪽으로 치우치지 않고 평하다. 우슬은 생것을 쓰면 어혈과 종기를 없애고, 찌면 간과 신을 보해 근육, 골격을 튼튼하게 한다. 어혈을 제거해줌으로 생리불순, 산후복통에 쓰며, 골수를 보충하고 음기를 잘 통하게 하여 관절염에 쓰고, 음허화동으로 인한 입안과 혀의 발진을 치료한다. 약리작용으로 자궁흥분작용, 콜레스테롤 강하작용, 이뇨작용, 혈당강하작용, 간기능 개선작용 등이 보고되었다. 생김새는 가늘고 긴 원주형의 원뿌리 또는 곁뿌리가 달린 원뿌리 형태이며 근두부는 약간의 근경이 붙어 있든가 또는 제거되어 있다. 원뿌리는 대개 막대모양이거나 또는 약간 구부러졌고 바깥면은 회황색 또는 황갈색이며 많은 세로주름과 드문드문 곁뿌리의 자국이 있다. 다른 이름으로 우경(牛莖), 백배(百倍), 산현채, 대절채(對節菜), 계교골(鷄膠骨)등이 있으며 특히 중국에서는 우슬을 하남성 회경(懷慶)산을 우량품으로 인정하여 회우슬(懷牛膝)이라고 부른다. The worm used in the present invention refers to the root of Achyranthes japonica Nakai or Achyranthes bidentata Blume in Korea and in Acyranthes bidentata Blume (牛膝) and Achyranthes fauriei H. Lev. & Vaniot). China recognizes only the Achyranthes bidentata Blume (牛 膝). There was a doctor who treated old bone or muscle disease, liver and kidney disease patients well, and decided to try to find a true disciple who was his successor. He decided to stay at the disciples' house with a fleeting pattern and watch their attitude. As a result, only the youngest disciple treated this moneyless mentally. The senator who applauded him told him the efficacy of herbal medicine and said, "He will save many people with this medicine because it is medicine to treat diseases of liver and kidney as well as bones and muscles." The disciples used this herb as a master 's will and became a name, and the appearance of the herb' s knuckles was like a cow 's knee and called' 牛 '. This medicine has little odor and is mucoid. The taste is a little bit spicy, and the quality is flat without any bias. If you use raw whiskey, you can eliminate the ejaculation and boils, and if you grind it, you will see the liver and the gods and strengthen the muscles and skeleton. It removes eosinophilia, and it is used for physiological impoverishment, postpartum abdominal pain. It replenishes bone marrow, it is used for arthritis with good sound, and it treats the mouth and tongue rash caused by the diarrhea. The pharmacological effects of uterine stimulation, cholesterol lowering, diuretic action, hypoglycemic action, and liver function improvement have been reported. Appearance is a long, long, circumferential circular root, or a circular root with a side root. The root head is attached or removed with a little rhizome. The roots are usually rod-shaped or slightly curved, and the outer surface is yellow or yellowish brown with many vertical wrinkles and sparse ridges. Other names include 牛 莖, hundredfold, mountain prefecture, 節节 菜, and 鷄 膠 骨. Especially in China, it is said that the mountain of Huanggang, It is called "虚 牛膝".
본 발명에 사용되는 당귀는 한국에서는 산형과 참당귀(Angelica gigas Nakai), 중국에서는 산형과 중국당귀(Angelica sinensis (Oliv.) Diels)의 건조시킨 뿌리를 말한다. 일본에서는 산형과 왜당귀(Angelica acutiloba (Siebold. & Zucc.) Kitag.) 또는 홋카이당귀(Angelica acutiloba (Siebold. & Zucc.) Kitag. var. sugiyamae Hikino)의 뿌리를 말려서 사용한다. 마땅히 돌아오기를 바란다는 뜻을 담아 '당귀(當歸)'라는 이름이 붙었다고 전해진다. 이는 오래 전 중국에서 부인들이 싸움터에 나가는 남편을 염려하며 품 속에 당귀를 넣어줬다는 풍습에 유래하는데, 전쟁터에서 기력이 다했을 때 당귀를 먹으면 다시 기운이 회복되어 돌아올 수 있다고 믿었기 때문이다. 일설에는 '이 약을 먹으면 기혈이 다시 제자리로 돌아온다'고 하여 지어진 이름이라고도 한다. 이 약재는 기운이 따뜻하고 맛은 달면서도 매운데, 일반적으로 참당귀가 중국당귀나 왜당귀에 비해 단맛은 약하고 매운맛이 강하다. 당귀의 효능은 피가 부족할 때 피를 생성해 주는 보혈 작용(補血作用)이 주를 이룬다. 중국당귀나 왜당귀의 뿌리로 만든 당귀는 보혈작용이 뛰어나다. 하지만 참당귀의 뿌리로 만든 당귀는 보혈작용보다는 피를 원활히 순환하게 해주는 활혈작용(活血作用)이 더 뛰어나며, 항암효과 및 혈압강하 작용이 강하다. 약리학적으로 당귀는 관상동맥의 혈류량을 촉진시키고, 적혈구 생성을 왕성하게 한다. 중국당귀는 약재의 껍질이 황갈색을 띠며 왜당귀와 참당귀는 어두운 갈색을 띤다. 약재의 단면은 중국당귀가 황갈색과 황색으로 선명한 편이나, 왜당귀는 황백색 또는 회백색, 참당귀는 어두운 황색 또는 유백색으로 중국당귀에 비해 색이 선명하지 않게 보인다. 또한 중국당귀의 경우 약재 단면에서 왜당귀나 참당귀에 비해 기름 성분을 관찰할 수 있다. 참당귀는 토당귀(土當歸), 숭검초, 조선당귀라고도 하고, 중국당귀는 당귀(當歸), 문귀(文歸), 건귀(乾歸), 대근(大芹), 상마(象馬), 지선원(地仙圓)이라고도 불리며, 왜당귀는 일당귀(日當歸)라고도 한다.The Angelica gigas Nakai used in the present invention refers to the dried root of Angelica gigas Nakai in Korea and the mountain type and Angelica sinensis (Oliv.) Diels in China. In Japan, the roots of Angelica acutiloba (Siebold. & Zucc.) Kitag. Or Angelica acutiloba (Siebold. & Zucc.) Kitag. Var. Sugiyamae Hikino) are dried and used. It is said that it is named 'Dangwi (当归)' with the intention of wanting to return. This is because the belief that long ago, in China, the wife put Angelica in her arms while worrying about her husband going to the battlefield, believing that when she was full of energy on the battlefield, her energy could be recovered again after eating Angelicae. Sometimes it is said to be named after "When you take this medicine, your blood will return to its original position." This medicinal herb is warm and tastes sweet and spicy. In general, Chrysanthemum angustifolia is stronger than Chinese Angelica and why it is sweet and has a pungent taste. The efficacy of angiosperms is due to the blood-producing (blood-clotting) action of producing blood when blood is scarce. Chinese Angelica, why Angelica, made from the root of Angelica gigas, is excellent in blood circulation. However, Angelica root, made from the root of Angelica gigas, has better anticancer effect and blood pressure lowering effect than antihypertensive action. Pharmacologically, Angelica promotes the blood flow of the coronary arteries and stimulates red blood cell production. Chinese angelica has a yellowish brown color in the skin of the medicinal material. Angelica and Angelica are dark brown. The cross section of the medicinal material shows clear yellowish yellow and yellowish color of Chinese angelica, but why the angelica is yellowish white or grayish white, and the angelica is dark yellow or milky white. In addition, in the case of Chinese Angelica gigas, the oil component can be observed in the cross section of the medicinal material compared to Angelica gigas and Angelica gigas. It is also called Chongryounggi, Chungsangganggu, and Chrysanthemum chinensis in Chinese. It is known that Chinese angelica (chrysanthemum) It is also called "仙 仙", and it is also called "귀 귀 일".
본 발명에 사용되는 숙지황은 지황(地黃)의 뿌리를 쪄서 말린 한약재로서, 지황은 현삼과에 딸린 여러해살이 약용식물로 그 뿌리를 한방에서 약재로 쓰는데, 날것을 생지황, 말린 것을 건지황이라 하며, 숙지황 중 특히 술에 담갔다가 쪄서 말리기를 9번 되풀이하여 만든 것은 구지황이라 하여 그 약효를 으뜸으로 친다. 맛은 달면서도 쓴맛이 돌고 따뜻한 성질이 있어 혈을 보(補)하고 정(精:생명이 발생하고 활동하는 데 기본이 되는 물질)을 보충해서 허리와 무릎이 시리고 아픈 증상이나 월경이상, 어지럼증 등을 치료하고 머리를 검게 하는 효능이 있다. 숙지황은 사물탕(四物湯)의 주요 약재이며 각종 만성병 중 몸이 허약하여 나타나는 내열(內熱), 인후건조(咽喉乾燥), 갈증 등의 증상에 쓰인다. 사물탕은 여성의 출산 후나 월경 등으로 인한 과다출혈, 허약, 어지럼증 등에 널리 쓰인다. 예로부터 허담(虛痰)을 치료하는 데 효과가 있어 차로 달여 마셨으며, 기침과 천식에 복령(茯笭)·반하(半夏) 등과 배합하여 사용하였다. 이밖에도 돼지고기를 삶은 국물과 함께 복용하면 습관성 변비에 효과가 있다. 영양분이 많고 기름기가 있어 장기간 복용하면 소화장애를 일으켜 설사·복창(腹脹) 등 부작용이 생긴다. 그러므로 입맛이 없고 소화가 안되며 설사를 하는 환자에게는 신중하게 사용해야 한다. As used in the present invention, Sukjihwang is a medicinal herb that is steamed and dried by the roots of Zhiwang (地 黄). Sichuan is a medicinal plant of perennial plant attached to the ginseng root, and its roots are used as medicines in one medicine. Especially in Sukjipguk, it is said that it is made by repeating 9 times of steaming and drying after soaking in alcohol. It has a bitter taste with a bitter taste, but it has a warm temperament, and it replenishes its blood and replenishes its essence (a substance that is fundamental to life and activity). It causes back and knee pain, sore symptoms, menstrual disorder, dizziness It has the efficacy to cure the head and darken the head. Sukjipang is the main medicinal material of Sangmangtang, and it is used for symptoms such as inner heat, sore throat, and thirst which are manifested by weakness of various chronic diseases. Samtang is widely used for excessive bleeding, weakness and dizziness caused by women's birth or menstruation. It has been effective in treating Huhdam (虛 痰) for a long time and drank for a long time by tea. It was used with cough and asthma in combination with gyeongryeong (茯 笭) and half-summer (half summer). In addition, boiled pork with broth is effective when taking habitual constipation. It has a lot of nutrients and it is greasy. If you take it for a long time, it causes digestive disorder and causes side effects such as diarrhea and repetition. Therefore, it should be used with caution in patients with no appetite, no digestion, and diarrhea.
본 발명에서 사용되는 작약은 미나리아재비과에 속하는 다년생 초본식물의 뿌리를 의미하며, 꽃이 크고 탐스러워서 함박꽃이라고도 한다. 백작약·적작약·호작약·참작약 등 다양한 품종이 있다. 성분은 배당체로서 파에오니플로린(paeoniflorin)과 알칼로이드인 파에오닌(paeonine)을 함유하고 탄닌·수지·안식향산도 있다. 약리적 작용으로는 흰쥐의 위장과 자궁의 평활근에 대하여 수축력을 약화시켰고, 토끼의 장관에는 진경(鎭痙) 효과를 나타내었다. 배당체 성분은 중추신경계를 억제한다. 이 밖에 항균작용이 있어서 황색포도상구균·이질균·용혈성연쇄상구균·폐렴쌍구균의 발육을 억제시킨다. 약성은 차고, 맛은 시고 쓰다. 위장염과 위장의 경련성동통에 진통효과를 나타내고, 소화장애로 복통·설사·복명(腹鳴)이 있을 때에 유효하며, 이질로 복통과 후중증이 있을 때에도 효과가 빠르다. 부인의 월경불순과 자궁출혈에 보혈·진통·통경의 효력을 나타낸다. 만성간염에도 사용되고 간장 부위의 동통에도 긴요하게 쓰인다. 또 빈혈로 인한 팔과 다리의 근육경련, 특히 배복근경련에 진경·진통 효과가 있다. 한방에서는 많이 쓰이는 약에 속하며, 민간에서는 빈혈에 사용한다. 금기로는 산후에 발열이 심할 때에는 복용을 삼간다. 대표적인 처방으로는 작약감초탕(芍藥甘草湯)이 있다.The peony used in the present invention refers to the root of a perennial herbaceous plant belonging to the family Ranunculaceae, There are a variety of varieties, such as peanuts, herbal medicines, herbal medicines, and medicines. The ingredient is a glycoside containing paeoniflorin and alkaloid paeonine, and tannin, resin and benzoic acid. The pharmacological actions of the rats weakened the contraction of the gastrointestinal tract and uterine smooth muscle, and showed a gastric (spasmodic) effect in the intestinal tract of the rabbit. The glycoside component inhibits the central nervous system. In addition, it has antimicrobial action, and it inhibits the development of Staphylococcus aureus, Disease, hemolytic streptococcus, and pneumococcus. The weakness is cold, the taste is bitter and bitter. It is effective when there is abdominal pain, diarrhea and abdominal pain due to gastroenteritis and gastrointestinal spastic pain, and it is effective even when there is abdominal pain after abdominal pain and diarrhea. It shows the efficacy of blood, pain, and blood transfusion in the menstrual irregularity and uterine bleeding. It is also used for chronic hepatitis and is also used for the pain of the liver. In addition, muscle spasms of the arms and legs caused by anemia, especially epigastric seizures, have epilepsy and analgesic effects. It belongs to medicine which is widely used in oriental medicine, and it is used for anemia in civilian. If the fever is severe in the postpartum period, do not take it. A typical prescription is peony liquorice (藥药 甘草 汤).
본 발명에서 사용되는 천궁은 미나리과의 여러해살이풀. 약용식물로 재배한다. 잎은 2회 3출 우상복엽이며 갈래조각은 난상 피침형이고 다소 깊은 톱니가 있다. 높이 30∼60cm이며 속이 비어 있고 가지가 다소 갈라진다. 잎은 어긋나고 2회 3출 깃꼴겹잎이며 갈래조각은 달걀 모양의 바소꼴이고 다소 깊은 톱니가 있다. 뿌리잎과 밑부분의 잎은 긴 잎자루가 있고 밑부분이 잎집으로 되어 줄기를 감싼다. 꽃은 8~9월에 피고 흰색이며 복산형꽃차례를 이룬다. 꽃잎은 5개이고 안쪽으로 말리며 수술은 5개, 암술은 1개이다. 총포와 소총포는 각각 5∼6개이며 줄 모양이다. 열매는 열리지만 성숙하지 않는다. 땅 속에 있는 마디 사이는 길이 5∼10cm, 지름 3∼5cm의 덩어리처럼 생기고 강한 향기가 있다. 정 ·진통 ·강장 등에 효능이 있어 두통 ·빈혈증 ·부인병 등을 치료하는데 쓴다. 9~11월에 근경을 캐어 잎과 줄기를 제거하고 햇볕에 말린후 3~6g을 달여서 복용하거나, 환제(丸劑)나 산제(散劑)로 하여 사용한다.As used in the present invention, it is a perennial plant of perennials. It is cultivated as a medicinal plant. Leaves are bifurcated in two thirds, with lanceolate lanceolate and somewhat deep sawtooth. It is 30 ~ 60cm in height, hollow inside and branch slightly. Leaves are alternate, two-folded three-queen-folded compound leaf, and the forked pieces are egg-shaped, with a slightly deep sawtooth. The leaves of the root and the bottom have long petiole, and the lower part forms a sheath, wrapping the stem. Flowers bloom from August to September, white and double-inflorescence. There are 5 petals and the inside is dry. There are 5 stamens and 1 pistil. The guns and the guns are 5 ~ 6 each in the shape of a line. The fruit is open but not mature. The nodules in the ground are like a lump of 5-10cm in length and 3-5cm in diameter and have a strong smell. It has efficacy for jeong, anal and tongue, and is used to treat headache, anemia, and women's diseases. Remove the leaves and stems from September to November, remove the stems, and dry them in the sun, then use 3 to 6g dalyeoseo, or use as a pill or powder.
본 발명에서 사용되는 구기자는 가짓과에 속하는 구기자나무의 열매로서, 구기자나무는 낙엽성 활엽관목(闊葉灌木: 넓은 잎의 떨기나무)으로 줄이 처져 있는 줄기는 보통 1∼1.5m 정도이고, 작은 가지가 변한 가시가 있는데, 없는 것도 있다.잎은 털이 없고 어긋나며 여러 개가 모여 나고, 톱니가 없는 난형(卵形) 또는 난상피침형이며, 끝이 뾰족하고 잎자루는 1㎝쯤 된다. 6∼9월에 자주빛 꽃이 잎의 겨드랑이에 1∼4개가 피며, 화관(花冠: 꽃부리)은 통상종형(筒狀鐘形: 대롱처럼 속이 비고 종처럼 생김)이고 끝이 다섯 갈래로 갈라져 있다. 열매는 원형 또는 타원형의 장과(漿果: 살과 물이 많고 씨앗이 있는 열매)이고, 8·9월에 붉게 익는다. 길이는 10㎜, 지름은 5㎜정도이다. 처음에는 달콤하나 나중에는 쓴 맛을 낸다. 건조시켰을 때에 겉이 쭈글쭈글하고, 속에는 많은 씨가 들어 있다. 씨는 편평하고 콩팥 모양이며, 지름이 약 2㎜ 정도이고 황백색이다. 열매의 모양과 색깔이 예쁘고 작아서 고서에는 ‘괴좃나무여름’이라고도 하였다. 현재 우리나라에서는 충청남도 청양군이 집산지이다. 성분은 베타인(betaine)·제아잔틴(zeazanthin)·카로틴(carotene)·티아민(thiamine), 비타민 A·B1·B2·C 등이 함유되어 있다. 동물을 실험한 결과, 베타인 성분은 생체내 대사물질의 하나인 친지질물질(親脂質物質: 지방에 가까운 물질)로 밝혀졌다. 간장에서 지방의 축적을 억제하고 간세포의 신생을 촉진하며, 혈압을 내려주는 작용도 한다. 약성(藥性)은 평범하고 독이 없다. 효능은 만성간염·간경변증 등에 복용하면 염증이 제거되고 기능을 활성화시킨다. 일반적으로 생식기능이 허약해서 허리·무릎이 저리고 아프고, 유정(遺精)·대하(帶下) 등의 증상에 유효하다. 안과질환으로 인한 시력감퇴 등에 효과가 있고, 노인의 백내장 초기증상에 응용한다. 구기자를 오래 복용하면 몸이 가벼워지고 기력이 왕성해지며, 다리·허리 등의 힘이 강해지고 세포의 노화를 억제하는 효과가 있다. 민간에서는 구기차(枸杞茶) 또는 구기주(枸杞酒)로 이용한다. 열이 있는 사람에게는 투여를 금한다. 한방에서는 강장제로 사용되고, 대표적인 처방으로 기국지황환(杞菊地黃丸)이 있다.As used in the present invention, the goji is a fruit of the gadfly tree belonging to the gadget family. The gadfly tree is a deciduous broad-leaved shrub (broad leaf bifurcated tree) with a stem of about 1 to 1.5 m in length, There are no thorns with small branches, but there are no thorns. The leaves have no hairs, and they are alternate phyllotaxis, ovate or ovate lanceolate, with pointed end and petiole about 1㎝. In June-September, purple flowers bloom on the sides of leaves with 1 to 4 blooms, corolla (corolla) is usually bell-shaped (like bell-shaped bell) and the end is divided into five branches . The fruit is a round or elliptical berry (fruit with lots of flesh and water and seeds) and ripens red in August and September. The length is 10 mm and the diameter is about 5 mm. It is sweet at first and bitter afterwards. When it is dry, it crumble on the outside, and there are many seeds inside. The seeds are flat, kidney-shaped, about 2mm in diameter and yellowish white. Because the shape and color of the fruit is pretty and small, it is said to be the "좃좃 木 夏" in ancient times. Currently, Cheongyang County in Chungcheongnam-do is the distribution center in Korea. Ingredients include betaine, zeazanthin, carotene, thiamine, and vitamins A, B1, B2, and C. Animal studies have shown that beta-linolenic acid is one of the in vivo metabolites of lipid (parent lipid). It inhibits the accumulation of fat in the liver, promotes hepatocyte development, and lowers blood pressure. Medicinal (medicinal) is mediocre and not poisonous. Efficacy of chronic hepatitis, liver cirrhosis, etc., when the inflammation is removed and the function is activated. Generally, the reproductive function is weak, and the back and the knee are sore, and it is effective for the symptoms such as the oiliness, the fatigue, and the fever. It is effective for the reduction of visual acuity due to ophthalmologic diseases and it is applied to the early symptoms of cataract in the elderly. Long-term use of gojija lighter and stronger energy, strengthening the legs and waist strength and has the effect of inhibiting the aging of cells. In the private sector, it is used as 枸杞 茶 or 기 酒. Do not administer to people with fever. In one room, it is used as a tonic, and as a typical prescription, there is a Kigyu Hwanghwang (杞 菊 地 黄 丸).
본 발명에서 사용되는 산수유는 층층나무과 산수유(山茱萸)나무의 열매로서, 타원형의 핵과(核果)로서 처음에는 녹색이었다가 8~10월에 붉게 익는다. 종자는 긴 타원형이며, 능선이 있다. 약간의 단맛과 함께 떫고 강한 신맛이 난다. 10월 중순의 상강(霜降) 이후에 수확하는데, 육질과 씨앗을 분리하여 육질은 술과 차 및 한약의 재료로 사용한다. 과육(果肉)에는 코르닌(cornin)·모로니사이드(Morroniside)·로가닌(Loganin)· 타닌(tannin)·사포닌(Saponin) 등의 배당체와 포도주산·사과산·주석산 등의 유기산이 함유되어 있고, 그밖에 비타민 A와 다량의 당(糖)도 포함되어 있다. 종자에는 팔미틴산·올레인산·리놀산 등이 함유되어 있다. 성분 중 코르닌은 부교감신경의 흥분작용이 있는 것으로 알려져 있다. 예로부터 한방에서는 과육을 약용하였다. 《동의보감》 《향약집성방》 등에 의하면 강음(强陰), 신정(腎精)과 신기(腎氣)보강, 수렴 등의 효능이 있다고 한다. 두통·이명(耳鳴)·해수병, 해열·월경과다 등에 약재로 쓰이며 식은땀· 야뇨증 등의 민간요법에도 사용된다. 차나 술로도 장복하며, 지한(止汗)· 보음(補陰) 등의 효과가 있다. 산수유나무는 한국·중국 등이 원산으로, 한국의 중부 이남에서 심는다. 국내에서는 전라남도 구례군 산동면과 경기도 이천시 백사면 일원, 경상북도 의성군 등에서 특산품으로 매년 출하하고 있다. The myrrh oil used in the present invention is the fruit of the stratum corneum and the myrtle tree. It is oval-shaped nucleus and is green at first, but ripens reddish from October to October. Seeds are long oval and have ridges. It has a bitter sweetness and strong acidity. It is harvested after the frost fall in mid-October. The flesh is separated from the seeds and the meat is used as a material for sake, tea and Chinese medicine. The pulp contains the glycosides such as cornin, Morroniside, Loganin, tannin and saponin and organic acids such as wine, malic acid and tartaric acid. In addition, it contains vitamin A and a large amount of sugars. Seeds include palmitic acid, oleic acid, linoleic acid and the like. Among the components, cornin is known to have an excitatory action of parasympathetic nerves. From the past, the pulp was weakened in one batch. According to the "Dongbibogam" and the "Fragrant Bulgari", it is said that it has effects such as strengthening of 阴 阴, 肾 精 and 肾气, and convergence. It is used as a medicinal product for headache, tinnitus, sea water, fever and menstrual overuse. It is also used for folk remedies such as cold sweat and enuresis. There are effects such as stopping sweat, consonance and so on. Sansui is native to Korea and China, and is planted in the middle of South Korea. In Korea, Shandong, Gyeonggi Province, Gyeonggi Province, Gyeonggi Province, and Gyeongsangbukdo, Yusung Gun, and other local products are shipped every year.
상술한 바와 같은 물에 배합되는 각 성분의 함량 및 추출온도와 시간은 본 발명자의 다양한 시험 속에서 여성 갱년기 증상 개선 및 혈액순환 증진을 위한 최적의 내용을 규정한 것이다.The content of each component and the temperature and time of extraction, as described above, in the various tests of the present inventors prescribe optimal contents for improvement of female menopausal symptoms and promotion of blood circulation.
또한 상술한 바와 같이 물에 혼합하여 열수 수출물로서 제조되어도 본 발명에서 원하는 기능을 충분히 달성하나 여성 갱년기 증상 개선 및 혈액순환 증진 등의 효과를 더욱 향상시키기 위하여 본 발명에서는 다음과 같은 과정을 더 추가할 수 있다.In addition, in order to sufficiently achieve the desired function of the present invention even though it is manufactured as a hot water export by mixing with water as described above, in order to further improve effects such as improvement of women's menopausal symptoms and improvement of blood circulation, can do.
돼지감자를 세척, 절단한 후 녹즙기를 이용하여 착즙하여 돼지감자 착즙액을 만들고 이어서 치커리를 세척한 후 녹즙기를 이용하여 착즙하여 치커리 착즙액을 만든 다음에 이들을 1:1의 중량비로 혼합하고 원심분리기를 통해 상기 착즙액을 원심분리하여 불용성 물질을 제거하며, 상기 원심분리한 착즙액에 상기 착즙액 대비 1중량%의 a-amylase를 첨가하여 전분을 분해한다. After washing and cutting the potatoes, the potato juice was poured using an untreated juice to make a potato juice. Then, the chicory was washed, and then the juice was poured using a green juice to make a chicory juice. The juice was mixed at a weight ratio of 1: , The insoluble matter is removed by centrifuging the juice solution, and 1% by weight of a-amylase is added to the juice solution by centrifugation to decompose the starch.
이후, 살균기를 통해 상기 전분 분해된 착즙액을 살균한 후, 살균된 착즙액을 원심분리하여 상등액만 수득하여 제조한 착즙액에 Aspergillus oryzae var. oryzae 곰팡이 균을 10중량% 접종하여 50℃에서 48시간 동안 발효하여 Aspergillus oryzae var. oryzae(KCTC No. 6596) 곰팡이 균이 배양된 착즙액을 만든다.Thereafter, the starch-decomposed juice was sterilized through a sterilizer, and the sterilized juice was centrifuged to obtain only the supernatant. Aspergillus oryzae var. oryzae fungus was inoculated at 10% by weight and fermented at 50 ° C for 48 hours to produce Aspergillus oryzae var. oryzae (KCTC No. 6596) Produces a juice solution in which fungi have been cultured.
이어서 이와 같은 발효 착즙액을 여과한 발효액 5ℓ를 물과 약제가 혼합된 혼합물에 부가한 후 50℃에서 48시간 동안 발효를 더 진행한 후에 상기 열수 추출을 하여 본 발명에 따른 건강식품 조성물을 제조할 수 있다. Subsequently, 5 L of the fermentation broth obtained by filtering the fermented juice solution was added to a mixture of water and a pharmaceutical agent, and the fermentation was further continued at 50 ° C for 48 hours, followed by hot water extraction to prepare a health food composition according to the present invention .
또한 본 발명에 따른 건강식품 조성물의 효능을 증가시키기 위하여 상기 사용되는 물이 수소수일 수 있는데, 본 발명의 수소수는 자화 처리, 초음파 처리, 광석 처리, 미네랄 처리, 또는 전기 분해 등의 방법에 의해 제조된다. 이들 방법 중 전기 분해 방법이 주로 사용되며, 전기 분해에 의해 제조된 수소수를 전해 수소수라 한다.전해 수소수는 알칼리 이온수 또는 수소 풍부수 등으로 불리며, 먹는 물, 미용, 산업 및 농업용 등으로 사용될 수 있다. 구체적으로, 전해 수소수는 아토피와 같은 피부염, 피부 미백, 노화, 생활 습관병 등에 효과가 있고, 노화 방지와 보습 효과로 화장품에도 사용될 수 있으며, 식품류 장기 원형 보존성에서 우수한 효과를 가진다. In order to increase the efficacy of the health food composition according to the present invention, the water used may be hydrogenated water. The hydrogenated water of the present invention may be used in a method such as magnetization treatment, ultrasonic treatment, ore treatment, mineral treatment, Lt; / RTI > Among these methods, electrolysis method is mainly used, and hydrogen water produced by electrolysis is referred to as electrolytic hydrogen water. Electrolytic hydrogen water is referred to as alkaline ion water or hydrogen rich water, and it is used for water, beauty, industrial and agricultural use . Specifically, electrolytic water has an effect on dermatitis such as atopic dermatitis, skin whitening, aging, lifestyle-related diseases, and can be used in cosmetics with anti-aging and moisturizing effects, and has excellent effects in long-term preservation of foods.
상술한 바와 같은 수소수를 이용하는 경우 본 발명에 따른 건강 식품 조성물의 효능은 현저하게 증가될 수 있다.When the above-mentioned water is used, the efficacy of the health food composition according to the present invention can be remarkably increased.
이하 실시예를 통하여 본 발명을 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in detail with reference to examples.
<< 실시예Example 1; 본 발명에 따른 조성물의 제조> One; Preparation of the composition according to the present invention >
물 20ℓ에 양파 4kg, 홍삼 1,200g, 두충 200g, 우슬 200g, 당귀 100g, 숙지황 100g, 작약 200g, 천궁 200g, 구기자 200g, 산수유 150g을 넣은 혼합물을 90℃에서 48시간 추출 후 여과하여 본 발명에 따른 조성물을 제조하였다.A mixture of 4 kg of onion, 1200 g of red ginseng, 200 g of ginseng, 200 g of Ganoderma lucidum, 100 g of Angelica gigas, 100 g of Ganoderma lucidum, 100 g of Ganoderma lucidum, 100 g of Ganoderma lucidum, 200 g of Ganoderma lucidum, 200 g of Gugija and 150 g of corn oil were added to 20 ℓ of water, A composition was prepared.
<< 실시예Example 2: 본 발명에 따른 조성물의 제조> 2: Preparation of composition according to the present invention >
돼지감자를 세척, 절단한 후 녹즙기를 이용하여 착즙하여 돼지감자 착즙액을 만들고 이어서 치커리를 세척한 후 녹즙기를 이용하여 착즙하여 치커리 착즙액을 만든 다음에 이들을 1:1의 중량비로 혼합하고 원심분리기를 통해 상기 착즙액을 원심분리하여 불용성 물질을 제거하며, 상기 원심분리한 착즙액에 상기 착즙액 대비 1중량%의 a-amylase를 첨가하여 전분을 분해하였다. 이후, 살균기를 통해 상기 전분 분해된 착즙액을 살균한 후, 살균된 착즙액을 원심분리하여 상등액만 수득하여 제조한 착즙액에 Aspergillus oryzae var. oryzae 곰팡이 균을 10중량% 접종하여 50℃에서 48시간 동안 발효하여 Aspergillus oryzae var. oryzae(KCTC No. 6596) 곰팡이 균이 배양된 착즙액을 만들었다. 이어서 이와 같은 발효 착즙액을 여과한 발효액 5ℓ를 상기 실시예 1의 물과 약제가 혼합된 혼합물에 부가한 후 50℃에서 48시간 동안 발효를 더 진행하였다.After washing and cutting the potatoes, the potato juice was poured using an untreated juice to make a potato juice. Then, the chicory was washed, and then the juice was poured using a green juice to make a chicory juice. The juice was mixed at a weight ratio of 1: And the insoluble matter was removed by centrifuging the juice solution. The starch was decomposed by adding 1 wt% of a-amylase to the juice solution by centrifugation. Thereafter, the starch-decomposed juice was sterilized through a sterilizer, and the sterilized juice was centrifuged to obtain only the supernatant. Aspergillus oryzae var. oryzae fungus was inoculated at 10% by weight and fermented at 50 ° C for 48 hours to produce Aspergillus oryzae var. oryzae (KCTC No. 6596) mold juice was cultured. Then, 5 liters of the fermentation broth filtered through the fermentation juice was added to the mixture of water and the pharmaceutical agent of Example 1, followed by further fermentation at 50 DEG C for 48 hours.
이 발효가 진행된 혼합물을 90℃에서 48시간 추출한 여과하여 본 발명에 따른 조성물을 제조하였다.The fermented mixture was extracted at 90 DEG C for 48 hours and filtered to prepare a composition according to the present invention.
<< 실시예Example 3: 본 발명에 따른 조성물의 제조> 3: Preparation of composition according to the present invention >
실시예 1과 동일한 방법으로 제조하였으며, 다만 정제수 대신에 수소수를 사용하는 것에서 차이가 있었으며, 수소수는 솔고바이오메디칼 디스펜서 수소샘 수소수제조기 [SHD-100]을 이용하여 제조한 것을 사용하였다.The same procedure as in Example 1 was used except that water was used instead of purified water. Hydrophobic water was prepared by using a solvent dispenser (SHD-100) manufactured by Solbi Biomedical Dispenser.
<< 실시예Example 4: 본 발명에 따른 조성물의 제조> 4: Preparation of composition according to the present invention >
실시예 3과 동일한 방법으로 제조하였으며, 다만 정제수 대신에 수소수를 사용하는 것에서 차이가 있었으며, 수소수는 솔고바이오메디칼 디스펜서 수소샘 수소수제조기 [SHD-100]을 이용하여 제조한 것을 사용하였다.The same procedure as in Example 3 was used except that water was used instead of purified water. Hydrophobic water was prepared by using a solvent dispenser (SHD-100) manufactured by Solbiomedical Dispenser.
<< 비교예Comparative Example : 비교 조성물의 제조>: Preparation of Comparative Composition >
비교예로서 사용할 조성물은 정제수 20ℓ에 홍삼 3kg, 당귀 200g, 작약 300g을 넣고 실시예 1과 동일한 온도와 시간으로 추출하여 제조하였다.The composition to be used as a comparative example was prepared by extracting 3 kg of red ginseng, 200 g of red ginseng and 300 g of peony root in 20 L of purified water at the same temperature and time as in Example 1.
<실험예 1 : 혈액순환 촉진 효과 실험><Experimental Example 1: Experimental Effect of Blood Circulation Promotion>
본 발명 혈액순환 촉진용 건강식품 조성물의 혈관확장효과를 측정하기 위하여 쥐(rats)의 하지동맥을 이용하여 KCl 유도 혈관수축에 대한 확장효과를 physiography로 측정하였다.In order to measure the vasodilating effect of the health food composition for promoting blood circulation according to the present invention, expansion effect on KCl-induced vasoconstriction was measured by physiography using the rats' lower limb artery.
실험동물로는 체중 20∼25g 내외의 스프라그-돌리(Sprague-Dawley)계 흰쥐(rat)를 항온, 항습이 유지되는 동물사육실에서 1주일 이상 적응시킨 후, 일반상태를 관찰하여 외관상 건강한 동물을 선별하여 10마리씩 2군(二群)으로 나누어 정상 대조군에게는 은행잎 엑기스를 급여하였고, 실험군에게는 실시예 1 내지 4 및 비교예 조성물을 식염수에 용해시켜 체중 250g당 0.14㎎으로 1일 1회 복강으로 급여하였다.As experimental animals, Sprague-Dawley rats weighing 20 ~ 25g were acclimated for more than 1 week in a constant temperature and humidity-maintained animal breeding room, The control group was fed with Ginkgo biloba extract and the experimental groups were dissolved in saline to give 0.14 mg per 250 g of body weight per day to the abdomen. Respectively.
KCl 72.7mM 유도 혈관수축에 대한 확장 실험의 결과를 하기 표 1하기 에 나타냈다.The results of the expansion experiment for KCl 72.7 mM induced vasoconstriction are shown in Table 1 below.
표준편차Mean ±
Standard Deviation
상기 표 1에서 보는 바와 같이, KCl 72.7mM 유도 혈관수축에 대한 본 발명의 건강식품 조성물이 은행잎 엑기스보다 혈관확장효과가 뛰어남을 확인할 수 있었으며, 반면에 비교예 조성물은 은행잎 엑기스보다는 혈관확장가 우수하지 않은 것으로 나타났다. 또한 본 발명에 따른 조성물의 경우에는 수소수를 사용한 조성물 및 발효 처리한 조성물에 더 우수하게 나타났다.As shown in Table 1, it was confirmed that the health food composition of the present invention against KCl 72.7 mM induced vasoconstriction had better vasodilating effect than Ginkgo biloba extract, whereas the comparative composition showed better vascular expansion than Ginkgo biloba extract Respectively. In addition, the composition according to the present invention was superior to the composition using hydrogen peroxide and the composition obtained by fermentation.
<실험예 2 : 동맥경화 억제효과 측정>Experimental Example 2: Measurement of inhibitory effect on arteriosclerosis [
상기 실험예 1에서 선별한 웅성흰쥐 10마리를 1군으로 하여 콜레스테롤 40m/㎏과 콜레칼시페롤 3200 IU/㎏을 동시에 올리브유에 용해시켜 28일 동안 1일 1회 경구투여하여 동맥경화증을 유발시켰다. 여기에 실시예 1 내지 4 및 비교예 조성물을 각각 0.250 g/㎏의 농도로 7일 동안 후처리하였다. 처리방법은 1일 1회 경구투여하고, 대조군에는 동량의 생리식염수만을 동일한 방법으로 경구투여하였다.Ten male rats selected in Experimental Example 1 were group 1, and cholesterol 40 m / kg and cholacilliprole 3200 IU / kg were dissolved in olive oil at the same time, and they were orally administered once a day for 28 days to induce arteriosclerosis . Herein, Examples 1 to 4 and Comparative Example compositions were each post-treated for 7 days at a concentration of 0.250 g / kg. The treatment method was orally administered once a day, and only the same amount of physiological saline was orally administered to the control group in the same manner.
실험 최종일에 대조군과 실험군을 12시간 동안 절식시킨 후 마취 하에서 복대동맥으로부터 채혈하였다. 얻은 혈액을 3000rpm 하에서 15분간 원심분리하여 용혈되지 않은 혈청을 채취한 다음, 효소법에 의하여 총 콜레스테롤의 함량, 총 콜레스테롤 중에 함유된 HDL-콜레스테롤의 함량을 측정하였으며, 혈청 중의 트리글리세라이드의 함량과 칼슘함량 은 각각 측정용 키트(kit)를 사용하여 측정하였다. 실험결과는 하기 표 2에 나타낸 바와 같다.On the last day of the experiment, the control group and the experimental group were fasted for 12 hours and blood was drawn from the abdominal artery under anesthesia. The obtained blood was centrifuged at 3000 rpm for 15 minutes to collect non-hemolyzed serum. Then, the total cholesterol content and the content of HDL-cholesterol contained in total cholesterol were measured by an enzymatic method, and the content of triglyceride and calcium content Were each measured using a measurement kit. The experimental results are shown in Table 2 below.
상기 표 2를 보면 대조군과 비교하여 본 발명의 조성물을 투여한 군이 전체적인 수치가 감소되어 우수한 효과를 보임을 알 수 있었으며, 비교예 조성물과 비교하여도 현저한 효과 증가를 확인할 수 있었다.The results are shown in Table 2. As shown in Table 2, the group administered with the composition of the present invention showed an excellent effect as compared with the control group.
<< 실험예Experimental Example 3: 혈액 중의 17β- 3: 17? estradiolestradiol 의 농도 측정 실험>Concentration measurement experiment>
21일령의 Sprague Dawley 암컷 흰쥐를 각 군당 5마리씩(평균체중 50g) 준비하고 5~6개월령의 흰쥐 역시 각 군당 5마리씩(평균체중 350g) 준비하여 상기 실시예 1 내지 4 및 비교예의 조성물을 30mg/kg body wt/day씩 3일간 경구투여 하였다.Five Sprague Dawley female rats at 21 days of age (average body weight: 50 g) were prepared for each group, and five rats at 5 to 6 months of age were also prepared for each group (average body weight: 350 g) to prepare the compositions of Examples 1 to 4 and Comparative Examples at 30 mg / kg body wt / day for 3 days.
시료 투여 전 혈액과 3일 투여 후 혈액 중의 17β-estradiol의 농도를 측정하였으며, 그 측정결과의 평균치는 하기 표 3에 나타냈다.The concentration of 17 [beta] estradiol in the blood before and 3 days after administration of the sample was measured. The average values of the results are shown in Table 3 below.
상기 표 3를 보면 본 발명의 조성물을 투여한 군이 전체적인 수치가 비교예의 조성물보다 현저하게 증가하였음을 확인할 수 있었으며, 특히 본 발명의 발효 처리한 실시예에서 더욱 우수한 효과를 나타났으며, 추출 용매로 수소수를 사용하는 경우에도 유의미한 정도의 효과 증가를 확인할 수 있었다.As shown in Table 3, it was confirmed that the total amount of the group administered with the composition of the present invention was significantly higher than that of the composition of the comparative example. In particular, the fermented example of the present invention showed more excellent effects, The use of hydrofluoric acid also showed a significant effect.
<< 실험예Experimental Example 4: 골다공증의 지표인 TRAP( 4: TRAP (an indicator of osteoporosis) TartrateTartrate -resistant acid -resistant acid phosphatase포스화제 ) 활성에 미치는 영향 확인>) Effect on activity>
본 실험예에서는 실시예 1 내지 4 및 비교예에서 제조한 조성물이TRAP(Tartrate-resistant acid phosphatase) 활성에 미치는 영향을 확인하고자 하였다. TRAP(Tartrate-resistant acid phosphatase)은 파골세포의 지표로 TRAP의 낮은 활성은 파골세포 분화가 억제되었음을 나타낸다.In this Experimental Example, effects of the compositions prepared in Examples 1 to 4 and Comparative Examples on the activity of TRAP (Tartrate-resistant acid phosphatase) were examined. Tartrate-resistant acid phosphatase (TRAP) is an indicator of osteoclast. Low activity of TRAP indicates that osteoclast differentiation is suppressed.
MC3T3-E1 세포를 파골세포로 분화시킬 목적으로 7주령 C57BL/6 암컷 마우스의 대퇴골 골수(femoral bone marrow) 세포를 적출하여, MC3T3-E1 세포와 함께 MEM 배양액(minimum essential medium, 10% FBS, 100 U/ml peniciline과 100 g/ml streptomycin)으로 배양하였다.In order to differentiate MC3T3-E1 cells into osteoclasts, femoral bone marrow cells of 7 week old C57BL / 6 female mice were harvested and cultured in MC3T3-E1 cells in MEM medium (10% FBS, 100% U / ml penicillin and 100 g / ml streptomycin).
MC3T3-E1 세포(1.5×104 cells/well)와, 골수(bone marrow) 세포(5×105 cells/well)를 24 웰 플레이트(well plate)에 시딩(seeding)하고, MEM 배양액에 10-8M 1,25(OH)2 vitamin D3, 10-7M 덱사메타손(dexamethasone)과 함께 시료(실시예 1 내지 4, 비교예)를 50 ㎍/ml 농도로 각각 처리해주었다. 배양액은 3일마다 교체하였고, 세포는 7일간 배양하였다. And MC3T3-E1 cells (1.5 × 10 4 cells / well ), bone marrow (bone marrow) cells (5 × 10 5 cells / well ) 10 to the seeding (seeding), and MEM culture medium in 24-well plate (well plate) - 8 M 1,25 (OH) 2 vitamin D 3 , and 10 -7 M dexamethasone were treated at a concentration of 50 μg / ml in each of the samples (Examples 1 to 4, Comparative Example). The culture medium was changed every 3 days, and the cells were cultured for 7 days.
7일간 배양 후, PBS(phosphate buffer saline)으로 세포를 두 번 세척하고, 세포용해 완충액(lysis buffer)을이용하여, 세포를 긁어(scrap) 수집한 후, 10초 간격으로 초음파처리(sonication)를 4회 시행하여 'cell lysate'를 수득하였다.After 7 days of incubation, the cells were washed twice with phosphate buffered saline (PBS), the cells were scraped using a lysis buffer, sonicated at 10 second intervals Cell lysate was obtained 4 times.
TRAP 활성도(TRAP activity) 측정 키트(kit)는 'Lifespan Biosciences'로부터 'ELISA [0056] kit'를 구입하여, 제조사 의 방법에 따라 450 nm에서 측정하였다.TRAP activity measurement kit was purchased from Lifespan Biosciences, and ELISA kit was purchased and measured at 450 nm according to the manufacturer's method.
'1,25(OH)2 vitamin D3'를 처리하지 않은 군을 일반군으로 하였으며, '1,25(OH)2 vitamin D3'를 처리한 후, 시료를 처리하지 않은 군을 대조군으로 하여, 그 결과는 하기 표 4에 나타내었다. 실험군간의 유의차는 'ANOVA' 분석을 사용하였으며, 유의성 평가는 p<0.05로 하였다.(1,25 (OH) 2 vitamin D 3 ') were treated as a normal group, and the control group was treated with 1,25 (OH) 2 vitamin D 3 , And the results are shown in Table 4 below. Significant differences between the experimental groups were analyzed using 'ANOVA' and significance was p <0.05.
상기 표 3를 보면 본 발명의 조성물을 투여한 군이 전체적인 수치가 대조군 및 비교예 조성물에 비하여 현저하게 감소하였음을 확인할 수 있었으며, 특히 본 발명의 발효 처리한 실시예에서 더욱 우수한 효과를 나타났으며, 추출 용매로 수소수를 사용하는 경우에도 유의미한 정도의 효과 증가를 확인할 수 있었다.As shown in Table 3, it was confirmed that the total amount of the group administered with the composition of the present invention was significantly lower than that of the control group and the comparative composition. In particular, the present invention was more effective in the fermentation of the present invention , And the use of hydrogen peroxide as an extraction solvent was also found to have a significant effect.
이상에서 살펴본 바와 같이 본 발명에 따른 조성물은 여성 갱년기 증상 개선 및 혈액순환 증진에 탁월한 효과를 보이는 것을 알 수 있다. As described above, it can be seen that the composition according to the present invention exerts an excellent effect in improving female menopausal symptoms and promoting blood circulation.
Claims (3)
To the mixture of 4 kg of onion, 1200 g of red ginseng, 200 g of ginseng, 200 g of Ganoderma lucidum, 100 g of Ganoderma lucidum, 100 g of Ganoderma lucidum, 100 g of Ganoderma lucidum, 200 g of Ganoderma lucidum, 200 g of ganoderma lucidum, 200 g of Gugija and 150 g of corn oil were added to 20 ℓ of water, After mixing with the weight ratio, a-amylase was added to decompose the starch, and then Aspergillus oryzae var. The oryzae fungus was inoculated with 10% by weight of the starch in the digestion solution and fermented at 50 DEG C for 48 hours. Then, 5 L of the fermented filtrate was added and the fermented product fermented at 50 DEG C for 48 hours was extracted at 90 DEG C for 48 hours The composition according to claim 1 or 2, wherein the composition is a composition for improving the symptoms of female menopausal symptoms and improving blood circulation.
The health food composition according to claim 1, wherein the water is hydrogenated to improve female menopausal symptoms and improve blood circulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170026509A KR101855821B1 (en) | 2017-02-28 | 2017-02-28 | Composition for relieving of menopausal symptoms and improving blood circulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170026509A KR101855821B1 (en) | 2017-02-28 | 2017-02-28 | Composition for relieving of menopausal symptoms and improving blood circulation |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101855821B1 true KR101855821B1 (en) | 2018-05-10 |
Family
ID=62184136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170026509A KR101855821B1 (en) | 2017-02-28 | 2017-02-28 | Composition for relieving of menopausal symptoms and improving blood circulation |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101855821B1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190142025A (en) * | 2018-06-15 | 2019-12-26 | 유한회사한풍제약 | Pharmaceutical composition and food composition for improving the symptoms of menopausal symptoms |
KR20200000943A (en) * | 2018-06-26 | 2020-01-06 | 주식회사 한국인삼공사 | Composition Comprising Red Ginseng Extract and Brassica oleracea Extract for Preventing or Treating Climacteric Syndrome |
WO2022086042A1 (en) * | 2020-10-20 | 2022-04-28 | 한국 한의학 연구원 | Composition for prevention, amelioration or treatment of poor ovarian responders caused by aging, comprising mixed medicinal herb extract as active ingredient |
KR20220167598A (en) | 2021-06-14 | 2022-12-21 | 주식회사 아우름글로벌 | Health functional food composition for women containing hyaluronic acid and manufacturing method thereof |
KR102555674B1 (en) | 2022-11-04 | 2023-07-18 | 주식회사 한미양행 | Composition containing Tenebrio molitor and Protaetia larva brevitarsis larva enzymatic hydrolysate for preventing or treating menopausal symptom |
KR20240071216A (en) | 2022-11-15 | 2024-05-22 | 국립한밭대학교 산학협력단 | Composition for improving blood flow and inflammation comprising acer mono sap |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100895969B1 (en) * | 2008-06-19 | 2009-05-07 | 창원대학교 산학협력단 | Development of concentrated onion extract having antioxidant and anticholesterol activities |
-
2017
- 2017-02-28 KR KR1020170026509A patent/KR101855821B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100895969B1 (en) * | 2008-06-19 | 2009-05-07 | 창원대학교 산학협력단 | Development of concentrated onion extract having antioxidant and anticholesterol activities |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190142025A (en) * | 2018-06-15 | 2019-12-26 | 유한회사한풍제약 | Pharmaceutical composition and food composition for improving the symptoms of menopausal symptoms |
KR102119672B1 (en) | 2018-06-15 | 2020-06-16 | 유한회사 한풍제약 | Pharmaceutical composition and food composition for improving the symptoms of menopausal symptoms |
KR20200000943A (en) * | 2018-06-26 | 2020-01-06 | 주식회사 한국인삼공사 | Composition Comprising Red Ginseng Extract and Brassica oleracea Extract for Preventing or Treating Climacteric Syndrome |
KR102073016B1 (en) | 2018-06-26 | 2020-02-04 | 주식회사 한국인삼공사 | Composition Comprising Red Ginseng Extract and Brassica oleracea Extract for Preventing or Treating Climacteric Syndrome |
WO2022086042A1 (en) * | 2020-10-20 | 2022-04-28 | 한국 한의학 연구원 | Composition for prevention, amelioration or treatment of poor ovarian responders caused by aging, comprising mixed medicinal herb extract as active ingredient |
KR20220167598A (en) | 2021-06-14 | 2022-12-21 | 주식회사 아우름글로벌 | Health functional food composition for women containing hyaluronic acid and manufacturing method thereof |
KR102555674B1 (en) | 2022-11-04 | 2023-07-18 | 주식회사 한미양행 | Composition containing Tenebrio molitor and Protaetia larva brevitarsis larva enzymatic hydrolysate for preventing or treating menopausal symptom |
KR20240071216A (en) | 2022-11-15 | 2024-05-22 | 국립한밭대학교 산학협력단 | Composition for improving blood flow and inflammation comprising acer mono sap |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101855821B1 (en) | Composition for relieving of menopausal symptoms and improving blood circulation | |
CN102048224B (en) | Red jujube health-care beverage capable of removing chloasma, beautifying features and improving skin, and production technology thereof | |
CN105454576A (en) | Jasmine-flower-comprising assorted Chinese herbal tea and preparation method thereof | |
CN103749821B (en) | A kind of gynostemma pentaphylla health-care tea improving immunity and preparation method thereof | |
CN107303006A (en) | Improve the composition of menopause symptom or osteoporosis | |
KR102243873B1 (en) | Fermented pills for reducing and preventing premature dementia and manufacturing methods thereof | |
KR100688252B1 (en) | Composition for improving male sexual function | |
CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
KR102127706B1 (en) | Preparation for improving blood circulation comprising mixed oriental medicinal extracts | |
KR20160000695A (en) | Herbal-medicine containing dha for recovering fatigue and enhancing memory, and method of manufacturing the same | |
KR101999675B1 (en) | Herbal composition for the prevention and treatment of coronary heart disease | |
CN105943619A (en) | Application of whole hemp extract in preparation of drug for preventing and treating Alzheimer's disease | |
TW202330006A (en) | Composition for preventing, improving or alleviating symptoms relating to qi deficiency and/or blood deficiency | |
KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
KR101934810B1 (en) | Preparation for improving blood circulation comprising oriental medicinal extracts | |
CN106822660A (en) | A kind of Chinese medicine preparation for treating cardiovascular and cerebrovascular disease | |
CN113456778A (en) | Composition for improving energy and preparation method thereof | |
KR20120024186A (en) | A composition of health supplementary food and method thereof | |
KR20170133820A (en) | Composition for relieving menopausal symptom or osteoporosis | |
CN104258224A (en) | Schisandra chinensis oral solution for treating lung-and-kidney yin-deficiency type chronic bronchitis and preparation method thereof | |
CN104983886A (en) | Traditional Chinese medicine preparation for treating constipation and preparing method thereof | |
KR101723962B1 (en) | Atopic dermatitis mitigate functional composition using environmentally friendly natural ingredients | |
KR101855820B1 (en) | Composition for improving hepatic function and enhancing stamina | |
KR101934811B1 (en) | Preparation for improving blood circulation comprising mixed medicinal extracts | |
KR102652335B1 (en) | Composition for preventing and improving woman climacterium symptoms comprising Glycine soja seed |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |